Create an account and get 3 free clips per day.
Chapters
Pancreatic Necrosis | Video-assisted Retroperitoneal Debridement | 58 | Male
Pancreatic Necrosis | Video-assisted Retroperitoneal Debridement | 58 | Male
2016abdominalassistedcollectioncollectionsdebridementdebrisdraindrainagedrainselevatedendoscopicinfectedinvasivenauseanecrotizingpancreaticpancreatitisparadigmparathyroidpatientpatientspercutaneousretroperitonealSIRsurgerysurgicaltechniquetract
Endoscopic vs. Open Vein Harvest For Bypasses: What Are The Advantages And Disadvantages Of Each
Endoscopic vs. Open Vein Harvest For Bypasses: What Are The Advantages And Disadvantages Of Each
advantagesautologousbypasscardiaccomorbidcomplicationsdecreasedecreaseddisadvantagesendoscopicendovascularextremityharvestincisionincreasedinexperiencedlaborligatedlowerpatencypatientspercutaneousperformedprimaryrisksaphenoussurgicalsuturevascularveinVeithwoundwounds
Extensive Heel Gangrene With Advanced Arterial Disease: How To Achieve Limb Salvage: The Achilles Tendon Is Expendable And Patients Can Walk Well Without It
Extensive Heel Gangrene With Advanced Arterial Disease: How To Achieve Limb Salvage: The Achilles Tendon Is Expendable And Patients Can Walk Well Without It
achillesadjunctiveadjunctsAllograftAllograft Amniotic membraneambulateBi-Layer Wound matrixBi-Layered Living Cell TherapybrachialdorsalendovascularexcisionheelincisionischemicmicrovascularmodalitiesneuropathynoninvasiveocclusiveoptimizedoptimizingOsteomyelitis / Heel Ulceration / Exposed Tendon / Sever PAD / DMpartialPartial or TotalpatientpatientsperforatingperipheralperonealPost Intervention in-direct Revascularizationposteriorposteromedialresectionrevascularizationrevascularizeskinspectrumtendontherapeutictibialtightlyulcerulcerationunderwentvascularwound
DEBATE: Not So: Why Open Bypass First Is Best In Some CLTI Patients: Which Ones: What Percent Of CLTI Patients Will Require An Open Procedure At Some Point In Their Course
DEBATE: Not So: Why Open Bypass First Is Best In Some CLTI Patients: Which Ones: What Percent Of CLTI Patients Will Require An Open Procedure At Some Point In Their Course
advancedamputationbypasscentercontemporarydataendoendovascularevarextremityfailedlimblimbsocclusionsOpen Bypassoutcomespatencypatientpatientspercentrevascularizationrisksecondarystagesurgerytolerate
Update On How To Diagnose And Treat Mixed Arterial And Venous Ulcers
Update On How To Diagnose And Treat Mixed Arterial And Venous Ulcers
algorithmamputationarterialautogenouscomponentcompressiondataDVTendovascularEVLTextremityhealhealingincisionsisolatedmichiganmixedmoderatepatientspercutaneousperforatorsrefluxrevascularizationrevascularizesummasuperficialtreatmentulcersvenouswoundwounds
Bailout Rescue Procedures When CEA Is Failing In A Critical Unstable Patient: ICA Stent Or Gore Hybrid Graft Or Standard PTFE Bypass: Indications For Each
Bailout Rescue Procedures When CEA Is Failing In A Critical Unstable Patient: ICA Stent Or Gore Hybrid Graft Or Standard PTFE Bypass: Indications For Each
anastomosisangiogrambailbypasscarotidCarotid bypassCEACFAdurableembolicendarterectomygoregrafthybridHybrid vascular graftinsertedlesionnitinolpatencypatientperioperativeproximalPTAptferestenosisstenosistechniquetransmuralvascular graft
What Are The Complications Of Spinal Fluid Drainage: How Can They Be Prevented: Optimal Strategies For Preventing Or Minimizing SCI
What Are The Complications Of Spinal Fluid Drainage: How Can They Be Prevented: Optimal Strategies For Preventing Or Minimizing SCI
aneurysmAneurysm repairaxisBEVARceliacchronicDialysisdraindrainagedrainseliminatedextentFEVARflowFluid / PressorsheadachehematomahemorrhagehypotensionincludingintracranialOccluded SMAoutcomespalliativeparaplegiapatientpatientsplacementpostoperativeprolongedprospectiveprotocolratesevereSevere PancreatitisspinalTEVARtherapeutictreated
A New System For Treating Prosthetic Arterial And Aortic Graft Infections
A New System For Treating Prosthetic Arterial And Aortic Graft Infections
abdominalanastomosisaneurysmbiofilmcomorbiditydebridementendovascularenterococcusexplantfasterfavorFemoro-femoral PTFE Bypass infectionfoamgraftinfectedinfectioninstillationintracavitarymalemortalitynegativeNPWTobservationalpatientpreservepressureprostheticptferadiologistremovalspecimensurgicaltherapythoracictreatmentvascularwound
New Developments In The Treatment Of Venous Thoracic Outlet Syndromes
New Developments In The Treatment Of Venous Thoracic Outlet Syndromes
angioplastyanterioranticoagulationantiplateletapproacharteryaxillaryBalloon angioplastycameracontraindicateddegreedischargeddrainduplexhematologyhypercoagulabilityincisionintraoperativelaparoscopicOcclusion of left subclavian axillary veinoperativePatentpatientspercutaneousPercutaneous mechanical thrombectomyperformingpleurapneumothoraxposteriorpostoppreoperativepulsatilereconstructionresectionsubclaviansurgicalthoracicthrombectomyTransaxillary First Rib ResectionTransaxillary First Rib Resection (One day later)uclavalsalvaveinvenogramvenographyvenousvisualization
Value And Limitations Of Cryopreserved Allografts For The Treatment Of Arterial Prosthetic Graft Infections
Value And Limitations Of Cryopreserved Allografts For The Treatment Of Arterial Prosthetic Graft Infections
adjunctiveaneurysmaorticarterialautologousbleedingcellulitisclosurecomplicationcomplicationsCryopreserved Allograftdeviceetiologyextremityfemoralgraftinfectedinfectioninfectionsinfectiousintraoperativelateligationlimbmycoticpatientspercutaneousperipheralprimaryprofundaprostheticpseudoaneurysmpseudoaneurysmsresectionscanseedingstenttherapeutictreatedulceratedvisceral
A RCT Comparing Medical Treatment vs. Thrombolysis And First Rib Resection For Venous TOS - Paget Schroetter Syndrome With Subclavian Vein Thrombosis
A RCT Comparing Medical Treatment vs. Thrombolysis And First Rib Resection For Venous TOS - Paget Schroetter Syndrome With Subclavian Vein Thrombosis
anticoagulationapproachbaselinecatheterCatheter-directed thrombolysisconservativedecompressiondeependpointextremityfavorFirst Rib Resectioninvasivemulticenterpatientpatientsprimaryrandomizationrandomizedrethrombosissyndrometherapythrombolysisthrombosistreatmenttrialupperveinvenographyvenousvillalta
Technical Tips To Make Distal Bypasses Work
Technical Tips To Make Distal Bypasses Work
anastomosisanesthesiaanestheticsangiogramangioplastyanticoagulationantiplateletarterybypassbypassesconduitdebridementdistaldistallydopplerdorsalisendarterectomyfootgrafthybridincisioninterventionischaemiaLeMaitrelevelOmniflow II Ovine graftsOrthograde graftspatientpatientspedisPeroneal BypasspoplitealprocedureproximalptferemoteRemote EndarterectomyrevascularizationsaphenousskinstentingSurveillancetherapytibialveinsvenouswaveform
Technical Tips For Open Conversion After Failed EVAR
Technical Tips For Open Conversion After Failed EVAR
AAAacuteantibioticaortaaorticAorto-Venous ECMOballooncirculatoryclampCoil Embolization of IMAcoilingconverteddeviceendarterectomyendograftendoleakendovascularentiregraftgraftsiliacinfectedinjection of gluepatientproximalRelining of EndograftremoveremovedrenalresectedRifampicin soaked dacron graftsupersutureTEVARtherapeutictranslumbartype
Importance Of Optimal Postoperative Glucose Management After Vascular Surgery: Why It Matters And What Are The Keys
Importance Of Optimal Postoperative Glucose Management After Vascular Surgery: Why It Matters And What Are The Keys
associatecarotidcomplicationscontroldiabeteselectiveendovascularevarextremityglucoseglycemichyperglycemiaincreasedinfectioninfectionsinfectiousinferiorlengthlookedlowermarkermortalityOAAA RepairoptimaloutcomespatientspostoperativeproceduresreadmissionrisksurgerysurgicalTherapeutic / Diagnostictimesundergoingvascular
Why Open Endarterectomy Is The Best Treatment For Common Femoral Artery Lesions: It Is Still The Gold Standard In Most Cases Despite What You May Read And Hear
Why Open Endarterectomy Is The Best Treatment For Common Femoral Artery Lesions: It Is Still The Gold Standard In Most Cases Despite What You May Read And Hear
amputationarterycommoncommon femoralembolizationendarterectomyendovascularfemoralfemoral arteryhematomaInterventionsmehtamorbiditymortalitypatencypatientsperioperativeprimaryrestenosisrevascularizationrotationalstentstentingstentssuperficialsurgicalsurvivalTECCO
Status Of Left Atrial Appendage Exclusion (Endo And Open) For Stroke Prevention With Atrial Fibrillation: Techniques And Results
Status Of Left Atrial Appendage Exclusion (Endo And Open) For Stroke Prevention With Atrial Fibrillation: Techniques And Results
afibAMPLATZER (Abbott) / AtriClip (AtriCure) / Lariat (SentreHEART) / WaveCrest (Coherex) / Occlutech (Occlutech) / LAmbre (Lifetech Scientific)approvedatrialAtriumBoston ScientificdevicedevicesendocardialexclusionfibrillationheartischemicLAA Closure DevicesleakleftLeft Atrial Appendage ClosurepatientspercentperfectrandomizedreducessafestsizedstrokesurgicaltherapeutictrialtypicallyWATCHMAN
Status Of Dual Layer Stents For CAS: Is Acute Occlusion An Issue And How To Avoid It
Status Of Dual Layer Stents For CAS: Is Acute Occlusion An Issue And How To Avoid It
acuteadequateantiplateletappositionarterybridgingcarotidcarotid stentcerebrovascularclopidogreldeploymentdualhighlightintravenouslylayermaneuvermeaningmedicationobservedocclusionpatientpatientsperformedporepredisposingpreparationpublicationsRoadSaverstenosisstentstentingstrokeTerumo interventional systemstherapythrombogenicthrombogenicityVeithwallstent
Current Management Of Bleeding Hemodialysis Fistulas: Can The Fistula Be Salvaged
Current Management Of Bleeding Hemodialysis Fistulas: Can The Fistula Be Salvaged
accessaneurysmalapproachArtegraftavoidbleedingbovineBovine Carotid Artery Graft (BCA)carotidcentersDialysisemergencyexperiencefatalFistulafistulasflapgraftgraftshemodialysishemorrhageinfectioninterpositionlesionLimberg skin flapnecrosispatencypatientpatientsptfeskinStent graftsubsequentsuturetourniquetulceratedulcerationsvascular
DEBATE: Endo-First Is Best For All CLTI Patients: Rarely Are Open Bypasses Helpful: How Often
DEBATE: Endo-First Is Best For All CLTI Patients: Rarely Are Open Bypasses Helpful: How Often
amputationbasilcriticaldistalendovascularevarextensivefemoralinfectionInfrapoplitealinterventionlimboutcomespatencypatientspoorrationalesalvagesegmentsurgerysurgicaltherapytibial
Estimation Of Long-Term Aortic Risk After EVAR: The LEAR Model: How Can It Guide And Modulate Surveillance Protocols
Estimation Of Long-Term Aortic Risk After EVAR: The LEAR Model: How Can It Guide And Modulate Surveillance Protocols
aneurysmaorticcentimeterdeviceendoleaksevarlearlowoutcomespatientpatientspredictorsregulatoryriskshrinkagestentsuprarenalSurveillanceVeith
Value Of Troponin Measurements Before All Vascular Procedures - Open Or Endo
Value Of Troponin Measurements Before All Vascular Procedures - Open Or Endo
accuracyamputationcardiacclinicalcomplicationscontrollingcorrelateddatadiagnosticelevatedelevationendovascularhazardhighlyidentificationindependentlevelsmajormorbiditymortalitypatientpatientsperioperativepostoperativepredictivepredictorpreoperativeprospectiveratioriskstratificationstudysurgerysurgicalsurvivalundergoingvascular
Optimal Timing Of CEA Or CAS After A Stroke Or TIA
Optimal Timing Of CEA Or CAS After A Stroke Or TIA
antiplateletcarotidcomplicationdaysendarterectomyhemorrhageinfarctionmechanicalpatientpatientsperformedrandomizedratesrecommendrisksstenosisstentingstrokesurgeryswedishsynchronousthrombectomyundergo
Pitfalls Of Percutaneous EVAR (PEVAR) And How To Avoid Them
Pitfalls Of Percutaneous EVAR (PEVAR) And How To Avoid Them
AbbottaccessanesthesiaAngio-Seal (Terumo Medical Corporation) - Closure deviceangiogramangiosealanteriorarteriotomybifurcationboreclampclosuredeployedEndologixevarfailedfailurefemoralgelfoamhemostasislengthmicropunctureobservedoperativePerclose ProGlidepercutaneousPEVARpredictorsprogliderandomizescarringSuture-Mediated Closure (SMC) Systemtechniquetherapeuticveitvenousvessel
Continued Tobacco Use Is Bad For PAD Patients But Does Not Negatively Affect Outcomes Of Endo Treatments For Intermittent Claudication
Continued Tobacco Use Is Bad For PAD Patients But Does Not Negatively Affect Outcomes Of Endo Treatments For Intermittent Claudication
activeadversebypasscessationclaudicationdemonstratedendovascularextremityfollowupinterventionlifelifestylelimblimitingmarkovmedicalmultidisciplinaryoutcomespatencypatientpatientsqualityrevascularizationsmokerssmokingsurgicaltobaccoversus
Rapid Transport For Acute Aortic Syndrome Patients: When Should It Be Used And When Not
Rapid Transport For Acute Aortic Syndrome Patients: When Should It Be Used And When Not
abdominalacuteaneurysmsaorticbasicallycenterscomorbiditycreatininedissectionsevarevarsfactorsinpatientinstitutionlowermortalitypatientsphysiologicpreoperativerapidrenalrupturedstudysyndromestransfertransferredtransferstransportunivariatevascularVeith
Thrombo-Embolic Complications Of Inflammatory Bowel Disease: Nature, Etiology And Significance
Thrombo-Embolic Complications Of Inflammatory Bowel Disease: Nature, Etiology And Significance
abdominalangiogramarterialatrialbowelcolectomycoloniccomplicationsdiseasedyslipidemiaetiologyextremityfibrinolyticheparinincidenceincreaseinflammatoryinpatientinpatientsischemicIV HeparinmedicalocclusionoccurringpatientsprophylaxispulmonaryresectionrevascularizationriskRt PE / Rt Pulm Vein thrombosis / Lt Atrial thrombosissidedSMA thrombectomysubtotalsystemicthrombectomythrombosisthrombotictransverseulcerativeunderwentveinvenousvisceral
New Developments In Access Site Closure For Small Sheaths; For Large Sheaths
New Developments In Access Site Closure For Small Sheaths; For Large Sheaths
ambulationantegradearteryassessingcalcifiedCardival Medicalcathcath labCelt ACD (Vasorum) - Vascular Closure DeviceclosurecollagencomplicationcomplicationscompressionconsconsecutivedeploymentdevicedevicesdiscembolizationfemoralhemostasismanualminorminutespatientsprosrandomizedrequiringretrogradestainlesssurgicaltherapeutictimetrialVascade VCDvascularVascular Closure Deviceversusvisualize
Converting Your Access Center From An Office-Based Surgery Center To An Ambulatory Care Facility
Converting Your Access Center From An Office-Based Surgery Center To An Ambulatory Care Facility
ambulatorycentercertificatefacilitymedicareofficepatientpatientspayorphysicianrequirementsrequiresstaffingsurgeryversus
Is Drug Neuroprotection After Thrombectomy For Acute Stroke Or Other Ischemic Cerebral Insults Feasible: Future Prospects
Is Drug Neuroprotection After Thrombectomy For Acute Stroke Or Other Ischemic Cerebral Insults Feasible: Future Prospects
acuteadvanceanteriorcarotidcerebralcollateralsdeliveryintracranialmechanicalneuroprotection agentsneuroprotectiveofferedpatientpatientsPenumbrapotentpreservestrokethrombectomyThromectomytpatreat
Patient Preferences For Open vs. Endo Repair For AAAs: How Are Patients Influenced And How Do Their Preferences Influence The Choice Of Procedure (From The PROVE-AAA RCT)
Patient Preferences For Open vs. Endo Repair For AAAs: How Are Patients Influenced And How Do Their Preferences Influence The Choice Of Procedure (From The PROVE-AAA RCT)
abdominalanatomicaneurysmaorticdecisiondegenerativeendovascularenrollenrollmentinfluencedmedicaloptionspatientsphysiologicpittsburghrepairstudysurgicaltreatmentvascularVeithversus
Selective SMA Stenting With F/EVAR: When Indicated, Value, Best Bridging Stent, Technical Tips
Selective SMA Stenting With F/EVAR: When Indicated, Value, Best Bridging Stent, Technical Tips
aneurysmcookdeviceselevatedendograftfenestratedfenestrationsFEVARgraftI-CAST(ZFEN)intensifiermidtermmortalityorthogonalpatientsrenalselectivestenosisstentstentedstentingtherapeutictreatedVBX (ZFEN)VeithvelocitiesvisceralwideZenith Fenestrated graft
Transcript

So the case that I'm presenting today is a 58-year-old man who presented to an outside hospital with upper abdominal pain nausea and vomiting. He had an elevated lipase, normal LFTs, no alcohol use, and a normal Right Upper Quadrant Ultrasound, i.e no stones.

But interestingly he had an elevated serum calcium and an elevated parathyroid hormone and surprise, surprise a very large left side parathyroid adenoma. He had this parathyroid adenoma resected but on post operative day two, his abdominal pain, nausea

and vomiting worsened, his lipase went higher and he basically got quite sick and was transferred to our ICU. Over the course of several weeks, he had multiple CT scans, the earlier CT scans showing your classic interstitial abdominis pancreatitis

with stranding. Subsequently,even with supportive measures, he had a CT scan that showed necrotizing pancreatitis and then eventually four weeks later after he went to rehab he developed early satiety, new nausea

and vomiting. Came back to our institution and developed walled off pancreatic necrosis. So how do we take care of that now? Certainly we can put drains into this. But I wanted to let you know,

or at least bring up this idea of multi modal or multimodality therapy because, this is sort of something that's really been a recent development in the treatment of necrotizing pancreatitis both from a percutaneous drainage stand point as well as endoscopic and surgical point of view.

So in order to access this collection one could actually debride through an endoscopic approach to the stomach. One could place a percutaneous drain as we see in several great examples already. But the thing that's really changing about the purpose of percutaneous drainage is the advent of new minimally invasive

surgical debridement techniques. i.e video scopic assisted retroperitoneal debridement. More and more centers in the US are doing that, I believe essentially in Europe this technique was pioneered and before I get into detail about that I want you to see what would have happened to this patient

5, 10, 15 years ago. Open surgical necrescetomy. So if this is a patient who may or may not have had percutaneous drainage, the drainage failed or didn't seem to make the patient better and the patient was clearly infected or acting infected i.e infected pancreatic necrosis,

these patients would got to surgery and essentially the patient would be filleted open and you see what kind of material you're dealing with. And the reason why sometimes drainage doesn't work. But surgery, open surgical necrosectomy is problematic with these patients often are septic after the procedure.

They end up with pancreatic and enteric fistulas. These patients have a 10% mortality after this kind of surgery. 10%. That's very high and so the question was or is that developed, is there a less invasive approach that would work just as well as open surgical debridement? Just to touch base about percutaneous drainage for this setting,

we've been draining these kinds of collections for decades. These are two papers in the same issue of radiology in 1988, describing percutaneous drainage and the thing to note is that even back then people noticed that there were challenges to putting drains into this.

One could certainly put a drain into it but the problem is if a lot of the cavities is filled solid necrotic debris and the patient was infected and acting sick i.e. sepsis in the ICU. One might not be able to wait days or weeks to allow the debris

to liquify and so these patients would have to go to surgery. So a lot of these patients were tried drainage first just to see if they can take the heat out of the fire and in some of the patients the drains work. But what's interesting if you look in the literature, the rate of

how many patients didn't have to go t surgery after drainage vary quite a bit. And in fact in this two papers in the same issue of radiology, in one paper 15% of patients no longer needed surgery and then the other paper 65% didn't need it.

So a wide variety in terms of the success of drainage and avoiding surgery and that partly has to do with selection bias. It probably has to do with drainage technique. But the thing to keep in mind is that this is what you're dealing with. Peter Miler at MGH, basically has an analogy what we are trying to drain here is dog meat.

And that you could put a straw or a garden hoes, getting this stuff out can take a lot of time with drainage and if the patient is sick you have to move a little bit. So the thing to keep in mind now is that we now have this new technique called VARD or Videoscopic Assisted Retroperitoneal Debridement

and that has changed the purpose of drainage. A number of these patients and we see severe cases where collections extend to the right, to the left cranial, cortal and to your posterior. I have had or seen patients with collections wherever the pancreatic juices go, it digests the patient and so you have collections surrounding

the bladder and the presacral space at the level of the acetabular, very extensive. Now, if this was not a pancreatitis patient, if we believed all of this was just purely liquid pus. That kind of patient we could put a drain in every collection and every corner of the abdomen pelvis that we see and we would have

a good shot at curing it, but that's not the case with necrotizing pancreatitis. A lot of this, despite the appearance of low attenuation on CT, a lot of this will be solid debris. So the new paradigm is in a lot of institutions now is to discuss with surgery, your surgeon and plan on where your drain tract will be

so that if the patient doesn't get better with drainage, then they can bring that patient to the OR and dissect along the drain tract and debris using their little laparoscorpic forceps and just pull the debris, just from a smaller incision along the drain tract. And so actually because of that paradigm shift and actually is there

a way to go back? [INAUDIBLE] there's the video there. And then you can actually see in this particular patient it can actually be hard to tell whether a patient has necrosis that's infected. And air within the collection is often a good sign but keep in mind that fistulising to bowel or an endoscopic procedure prior to your drainage procedure,

prior to the CT can also give you air in that collection. This is just a seldinger technique showing you placement of a 24 French fall tube as we just had in that collection. These tracks were chosen in conjunction or after discussion with surgery.

So that they can plan the most efficient safest approach for their debridement. And the things you look out for, obviously the most common parts to look out for is going to be the colon, the spleen and the kidney.

Now you have this paradigm shift. Now we're seeing more and more of these patients going straight to drainage first rather than keeping the patient in the ICU for a long period of time. And if absolutely they needed to come down to IR for a sort of Hail Mary drainage.

And more and more articles in the surgical literature are now saying drain first but the caveat is drain better. And what I mean by better is bigger is better. So this is just an example of a 10 French drain that you might use for your standard tissue diverticulitis abscess.

But this is an example of the fall tube that Horacio had just mentioned 24 french. nd the reason why we use such large tubes, is one because it reduces the risk of clogging. It also allows a better tract to develop so that the surgeon can go down that tract in a much more reliable fashion.

- Good morning. I'd like to thank Dr. Veith and Symposium for my opportunity to speak. I have no disclosures. So the in Endovascular Surgery, there is decrease open surgical bypass. But, bypass is still required for many patients with PAD.

Autologous vein is preferred for increase patency lower infection rate. And, Traditional Open Vein Harvest does require lengthy incisions. In 1996 cardiac surgery reported Endoscopic Vein Harvest. So the early prospective randomized trial

in the cardiac literature, did report wound complications from Open Vein Harvest to be as high as 19-20%, and decreased down to 4% with Endoscopic Vein Harvest. Lopes et al, initially, reported increase risk of 12-18 month graft failure and increased three year mortality.

But, there were many small studies that show no effect on patency and decreased wound complications. So, in 2005, Endoscopic Vein Harvest was recommended as standard of care in cardiac surgical patients. So what about our field? The advantages of Open Vein Harvest,

we all know how to do it. There's no learning curve. It's performed under direct visualization. Side branches are ligated with suture and divided sharply. Long term patency of the bypass is established. Disadvantages of the Open Vein Harvest,

large wound or many skip wounds has an increased morbidity. PAD patients have an increased risk for wound complications compared to the cardiac patients as high as 22-44%. The poor healing can be due to ischemia, diabetes, renal failure, and other comorbid conditions.

These can include hematoma, dehiscense, infection, and increased length of stay. So the advantages of Endoscopic Vein Harvest, is that there's no long incisions, they can be performed via one or two small incisions. Limiting the size of an incision

decreases wound complications. It's the standard of care in cardiac surgery, and there's an overall lower morbidity. The disadvantages of is that there's a learning curve. Electro-cautery is used to divide the branches, you need longer vein compared to cardiac surgery.

There's concern about inferior primary patency, and there are variable wound complications reported. So recent PAD data, there, in 2014, a review of the Society of Vascular Surgery registry, of 5000 patients, showed that continuous Open Vein Harvest

was performed 49% of the time and a Endo Vein Harvest about 13% of the time. The primary patency was 70%, for Continuous versus just under 59% for Endoscopic, and that was significant. Endoscopic Vein Harvest was found to be an independent risk factor for a lower one year

primary patency, in the study. And, the length of stay due to wounds was not significantly different. So, systematic review of Endoscopic Vein Harvest data in the lower extremity bypass from '96 to 2013 did show that this technique may reduce

primary patency with no change in wound complications. Reasons for decreased primary patency, inexperienced operator, increased electrocautery injury to the vein. Increase in vein manipulation, you can't do the no touch technique,

like you could do with an Open Harvest. You need a longer conduit. So, I do believe there's a roll for this, in the vascular surgeon's armamentarium. I would recommend, how I use it in my practices is, I'm fairly inexperienced with Endoscopic Vein Harvest,

so I do work with the cardiac PA's. With increased percutaneous procedures, my practice has seen decreased Saphenous Vein Bypasses, so, I've less volume to master the technique. If the PA is not available, or the conduit is small, I recommend an Open Vein Harvest.

The PA can decrease the labor required during these cases. So, it's sometimes nice to have help with these long cases. Close surveillance follow up with Non-Invasive Arterial Imaging is mandatory every three months for the first year at least. Thank you.

- Good morning. It's a pleasure to be here today. I'd really like to thank Dr. Veith, once again, for this opportunity. It's always an honor to be here. I have no disclosures. Heel ulceration is certainly challenging,

particularly when the patients have peripheral vascular disease. These patients suffer from significant morbidity and mortality and its real economic burden to society. The peripheral vascular disease patients

have fivefold and increased risk of ulceration, and diabetics in particular have neuropathy and microvascular disease, which sets them up as well for failure. There are many difficulties, particularly poor patient compliance

with offloading, malnutrition, and limitations of the bony coverage of that location. Here you can see the heel anatomy. The heel, in and of itself, while standing or with ambulation,

has tightly packed adipose compartments that provide shock absorption during gait initiation. There is some limitation to the blood supply since the lateral aspect of the heel is supplied by the perforating branches

of the peroneal artery, and the heel pad is supplied by the posterior tibial artery branches. The heel is intolerant of ischemia, particularly posteriorly. They lack subcutaneous tissue.

It's an end-arterial plexus, and they succumb to pressure, friction, and shear forces. Dorsal aspect of the posterior heel, you can see here, lacks abundant fat compartments. It's poorly vascularized,

and the skin is tightly bound to underlying deep fascia. When we see these patients, we need to asses whether or not the depth extends to bone. Doing the probe to bone test

using X-ray, CT, or MRI can be very helpful. If we see an abcess, it needs to be drained. Debride necrotic tissue. Use of broad spectrum antibiotics until you have an appropriate culture

and can narrow the spectrum is the way to go. Assess the degree of vascular disease with noninvasive testing, and once you know that you need to intervene, you can move forward with angiography. Revascularization is really operator dependent.

You can choose an endovascular or open route. The bottom line is the goal is inline flow to the foot. We prefer direct revascularization to the respective angiosome if possible, rather than indirect. Calcanectomy can be utilized,

and you can actually go by angiosome boundaries to determine your incisions. The surgical incision can include excision of the ulcer, a posterior or posteromedial approach, a hockey stick, or even a plantar based incision. This is an example of a posterior heel ulcer

that I recently managed with ulcer excision, flap development, partial calcanectomy, and use of bi-layered wound matrix, as well as wound VAC. After three weeks, then this patient underwent skin grafting,

and is in the route to heal. The challenge also is offloading these patients, whether you use a total contact cast or a knee roller or some other modality, even a wheelchair. A lot of times it's hard to get them to be compliant.

Optimizing nutrition is also critical, and use of adjunctive hyperbaric oxygen therapy has been shown to be effective in some cases. Bone and tendon coverage can be performed with bi-layered wound matrix. Use of other skin grafting,

bi-layered living cell therapy, or other adjuncts such as allograft amniotic membrane have been utilized and are very effective. There's some other modalities listed here that I won't go into. This is a case of an 81 year old

with osteomyelitis, peripheral vascular disease, and diabetes mellitus. You can see that the patient has multi-level occlusive disease, and the patient's toe brachial index is less than .1. Fortunately, I was able to revascularize this patient,

although an indirect revascularization route. His TBI improved to .61. He underwent a partial calcanectomy, application of a wound VAC. We applied bi-layer wound matrix, and then he had a skin graft,

and even when part of the skin graft sloughed, he underwent bi-layer living cell therapy, which helped heal this wound. He did very well. This is a 69 year old with renal failure, high risk patient, diabetes, neuropathy,

peripheral vascular disease. He was optimized medically, yet still failed to heal. He then underwent revascularization. It got infected. He required operative treatment,

partial calcanectomy, and partial closure. Over a number of months, he did finally heal. Resection of the Achilles tendon had also been required. Here you can see he's healed finally. Overall, function and mobility can be maintained,

and these patients can ambulate without much difficulty. In conclusion, managing this, ischemic ulcers are challenging. I've mentioned that there's marginal blood supply, difficulties with offloading, malnutrition, neuropathy, and arterial insufficiency.

I would advocate that partial or total calcanectomy is an option, with or without Achilles tendon resection, in the presence of osteomyelitis, and one needs to consider revascularization early on and consider a distal target, preferentially in the angiosome distribution

of the posterior tibial or peroneal vessels. Healing and walking can be maintained with resection of the Achilles tendon and partial resection of the os calcis. Thank you so much. (audience applauding)

- Thank you and thanks Craig, it's fun to have these debates with good colleagues, thoughtful colleagues. These are my disclosures for the talk. But pry my most important disclosure is I work in academic center with a dedicated Limb Preservation Center, very tertiary practice. And I perform both open and endovascular surgery

and actually my current lower extremity practice is probably about 60 to 65 percent endovascular so, I do both of these procedures. We already saw this slide about how the increase in endovascular intervention has grown. But, I would caution you to look a little more closely

at this outpace of decline in bypass surgery by more than three to one. I don't think this is an epidemic, I think it's a little bit of this, and a little bit of this. Everything looks like a nail when you only have a hammer

or a hammer when you only have a nail. So, what should we really be doing today? We should be trying to select the best thing for the right patient at the right time. And it really comes down to starting not with the lesion, but with the patient.

Start with assessing the patient's risk, what's their perioperative risk, what's their long-term survival, what are their goals for care? And then look at the limb itself, because not all limbs are the same.

There are minor ulcers, there's extensive and severe rest pain and there are large areas of tissue loss. And the WIfI system is good for that. And then let's look at the anatomy last. And when we're looking at it from the standpoint of what all the options are, endovascular we're looking

at what's the likelihood not just of technical success, but of hemodynamic gain and sustained patency for as long as a patient needs it. With bypass, we also have to look at other things. What kind of vein do they have, or what kind of target do they have?

And I think the bottom line here is in today's practice, it's kind of silly to say endo first for all patients, it's certainly not surgery first for all patients because they have complementary roles in contemporary practice. Well what's happening in the world out there,

this is the German CRITISCH registry, I'll just point out 12 hundred patients recently published only a couple of years ago, 24 percent of patients get bypass first. And if you look at who they are, not surprisingly they are the patients

with long occlusions and complex anatomy. They are out there, in fact most of these patients have multi-segment disease, as Craig pointed out. Here's some contemporary data that you haven't seen yet because it's in press, but this is VQI data looking at 2003 to 2017.

I'll point out just in the last 2013 years, still, if you looked at unique patients, not procedures, one-third of the patients are getting a bypass first. And if you define risk groups considering what might be a low risk patient as a three percent mortality and survival greater than 70 percent,

and a high risk patient, you can put these patients into buckets and in fact, of all the patients getting lower extremity revascularization and VQI today, 80 percent of them would be called low risk based on this definition. So, most patients are not high risk patients

who don't have long-term survival. In fact, this is current VQI data. If you're a low risk patient in that cohort, your five year survival actually is over 70 percent. So there's a lot of these patients actually today with better CLO medical therapy that are actually

living longer and are not that high risk. We talked about the BASIL trial already, and he pointed out how the early results were similar, but what we learned also with BASIL, that if you've got a bypass as a secondary procedure, or if you got a bypass with a prosthetic,

you simply did not do as well. That doesn't mean that the initial endovascular revascularization caused the bypass failure, but it means that secondary bypass surgery does not work as well. And when Dr. Bradbury looked at this data

over a longer period of time now going over many more years, there's a consistent inferior outcome to the patients who had their bypass after failed angioplasty in comparison to bypass as the initial strategy. This is not an isolated finding. When we looked in the VSGNE data over a,

more than 3000 patients at the impact of restenosis on subsequent treatment failure, we found that whether patients had a failed previous PVI or bypass, their secondary bypass outcomes were inferior, and the inferiority continued to get worse with time.

These bypasses just don't perform as well. Unfortunately, if we only do bypass after endo has failed, this is what all the results are going to start to look like. So let's be a little bit smarter. Now what about patency?

I think we, even today in the endovascular world, we realize patency is important. After all, that's why we're doing drug elution. Most, but not all patients with advanced limb ischemia will recrudesce their symptoms when their revascularization fails.

I think we all know that. Most CLTI patients have multi-segment disease. I don't want to sit up here and be a high school or elementary school math teacher, but here's the reality. If you look at it above the lesion, you say I'm going to get 70 percent patency there, and you look at

the tibial lesion, you say I'm going to get 50 percent patency there, what do you think your patency is for the whole leg? It's 35 percent folks, it's the product of the two. That is the reality pretty often. Patients with more advanced limb presentations,

such as WIfI stage do not tolerate these failures. They tolerate them poorly. They go on to amputation pretty fast. And patient survival, as I've already shown you has improved. Now, what the all endo-all the time

camp does and doesn't say. He already showed us, many datasets suggest the downstream outcomes are roughly equivalent but, these are not the same patients, we are not operating on the same patients you are doing endo on.

If I told you the results are the same for PCI and CABG without showing you anatomy, you would laugh me off the stage right? So, this is really not an equivalent argument. Endo can be repeated with minimal morbidity, but patients suffer.

Their limb status deteriorates, they come in the hospital often, and they continue to decline in the outcomes of these secondary procedures. CLTI patients are too frail for surgery, I just showed you that's really not true for many patients.

There is really unfortunately, an economic incentive here. Because there is unfortunately, no incentive for durable success. I hate to bring that up, but that's the reality. Now just quickly, some results. This is a large Japanese series

where they were performing endovascular interventions only for advanced limb ischemia. And basically what you can see as you go across the WIfI stages here from stage one to stage four, when you get to these stage four patients, the wound healing rate's only 44 percent,

limb salvage rate drops to 80 percent, repeat EVT rate is encroaching 50 percent. These patients really are not doing well with endovascular intervention. And we found that in our own series too, it's relatively small numbers and not randomized.

But if we look at the stage 4 limbs with bypass versus endo, when these patients failed at revascularization, and they may not have been bypass candidates, but they didn't do well, they went on to amputation very quickly.

So the ESC guidelines that just came out really sort of line up with what I'm telling you. You'll see bypass first. If you have long occlusions in an available vein, is actually currently the favorite approach, with level 1A recommendation.

So in summary, this is how I currently approach it. You look at all these factors, some people should get endo first, but there's still about 20 or 30 percent that I think should get bypass. Some people should go on to amputation earlier, is the bottom line, and I'll go right to the bottom line.

If you don't have access to a skilled open bypass surgeon, you're probably not at a center of excellence, go find one.

- Thank you, thanks for the opportunity to present. I have no disclosures. So, we all know that wounds are becoming more prevalent in our population, about 5% of the patient population has these non-healing wounds at a very significant economic cost, and it's a really high chance of lower extremity amputation

in these patients compared to other populations. The five-year survival following amputation from a foot ulcer is about 50%, which is actually a rate that's worse than most cancer, so this is a really significant problem. Now, even more significant than just a non-healing wound

is a wound that has both a venous and an arterial component to it. These patients are about at five to seven times the risk of getting an amputation, the end patients with either isolated venous disease or isolated PAD. It's important because the venous insufficiency component

brings about a lot more inflammation, and as we know, this is associated with either superficial or deep reflux, a history of DVT or incompetent perforators, but this adds an increasing complexity to these ulcers that refuse to heal.

So, it's estimated now about 15% of these ulcers are more of a mixed etiology, we define these as anyone who has some component of PAD, meaning an ABI of under point nine, and either superficial or deep reflux or a DVT on duplex ultrasound.

So we're going to talk for just a second about how do we treat these. Do we revascularize them first, do we do compression therapy? It has been shown in many, many studies, as with most things, that a multi-disciplinary approach

will improve the outcome of these patients, and the first step in any algorithm for these patients involves removing necrotic and infected tissue, dressings, if compression is feasible, based on the PAD level, you want to go ahead and do this secondary, if it's not, then you need to revascularize first,

and I'm going to show you our algorithm at Michigan that's based on summa the data. But remember that if the wounds fail to heal despite all of this, revascularization is a good option. So, based on the data, the algorithm that we typically use is if an ABI is less than point five

or a toe pressure is under 50, you want to revascularize first, I'll talk for a minute about the data of percutaneous versus open in these patients, but these are the patients you want to avoid compression in as a first line therapy.

If you have more moderate PAD, like in the point five to point eight range, you want to consider compression at the normal 40 millimeters of mercury, but you may need to modify it. It's actually been shown that that 40 millimeter of mercury

compression actually will increase flow to those wounds, so, contrary to what had previously been thought. So, revascularization, the data's pretty much equivocal right now, for these patients with these mixed ulcers, of whether you want to do endovascular or open. In diabetics, I think the data strongly favors

doing an open bypass if they have a good autogenous conduit and a good target, but you have to remember, in these patients, they have so much inflammation in the leg that wound healing from the surgical incisions is going to be significantly more difficult

than in a standard PAD patient, but the data has shown that about 60% of these ulcers heal at one year following revascularization. So, compression therapy, which is the mainstay either after revascularization in the severe PAD group or as a first line in the moderate group,

is really important 'cause it, again, increases blood flow to the wound. They've shown that that 40 millimeters of mercury compression is associated with a significant healing rate if you can do that, you additionally have to be careful, though,

about padding your bony areas, also, as we know, most patients don't actually keep their compression level at that 40, so there are sensors and other wearable technologies that are coming about that help patients with that, keeping in mind too, that the venous disease component

in these patients is really important, it's really important to treat the superficial venous reflux, EVLT is kind of the standard for that, treatment of perforators greater than five, all of that will help.

And I'm not going to go into any details of wound dressings, but there are plenty of new dressings that are available that can be used in conjunction with compression therapy. So, our final algorithm is we have a patient with these mixed arterial venous ulcers, we do woundcare debridement, determine the degree of PAD,

if it's severe, they go down the revascularization pathway, followed by compression, if it's moderate, then they get compression therapy first, possible treatment of venous disease, if it still doesn't heal at about 35 weeks, then you have to consider other things,

like biopsy for cancer, and then also consider revacularization. So, these ulcers are on a rise, they're a common problem, probably we need randomized control trials to figure out the optimal treatment strategies.

Thank you.

- Thank you very much, Frank, ladies and gentlemen. Thank you, Mr. Chairman. I have no disclosure. Standard carotid endarterectomy patch-plasty and eversion remain the gold standard of treatment of symptomatic and asymptomatic patient with significant stenosis. One important lesson we learn in the last 50 years

of trial and tribulation is the majority of perioperative and post-perioperative stroke are related to technical imperfection rather than clamping ischemia. And so the importance of the technical accuracy of doing the endarterectomy. In ideal world the endarterectomy shouldn't be (mumbling).

It should contain embolic material. Shouldn't be too thin. While this is feasible in the majority of the patient, we know that when in clinical practice some patient with long plaque or transmural lesion, or when we're operating a lesion post-radiation,

it could be very challenging. Carotid bypass, very popular in the '80s, has been advocated as an alternative of carotid endarterectomy, and it doesn't matter if you use a vein or a PTFE graft. The result are quite durable. (mumbling) showing this in 198 consecutive cases

that the patency, primary patency rate was 97.9% in 10 years, so is quite a durable procedure. Nowadays we are treating carotid lesion with stinting, and the stinting has been also advocated as a complementary treatment, but not for a bail out, but immediately after a completion study where it

was unsatisfactory. Gore hybrid graft has been introduced in the market five years ago, and it was the natural evolution of the vortec technique that (mumbling) published a few years before, and it's a technique of a non-suture anastomosis.

And this basically a heparin-bounded bypass with the Nitinol section then expand. At King's we are very busy at the center, but we did 40 bypass for bail out procedure. The technique with the Gore hybrid graft is quite stressful where the constrained natural stint is inserted

inside internal carotid artery. It's got the same size of a (mumbling) shunt, and then the plumbing line is pulled, and than anastomosis is done. The proximal anastomosis is performed in the usual fashion with six (mumbling), and the (mumbling) was reimplanted

selectively. This one is what look like in the real life the patient with the personal degradation, the carotid hybrid bypass inserted and the external carotid artery were implanted. Initially we very, very enthusiastic, so we did the first cases with excellent result.

In total since November 19, 2014 we perform 19 procedure. All the patient would follow up with duplex scan and the CT angiogram post operation. During the follow up four cases block. The last two were really the two very high degree stenosis. And the common denominator was that all the patients

stop one of the dual anti-platelet treatment. They were stenosis wise around 40%, but only 13% the significant one. This one is one of the patient that developed significant stenosis after two years, and you can see in the typical position at the end of the stint.

This one is another patient who develop a quite high stenosis at proximal end. Our patency rate is much lower than the one report by Rico. So in conclusion, ladies and gentlemen, the carotid endarterectomy remain still the gold standard,

and (mumbling) carotid is usually an afterthought. Carotid bypass is a durable procedure. It should be in the repertoire of every vascular surgeon undertaking carotid endarterectomy. Gore hybrid was a promising technology because unfortunate it's been just not produced by Gore anymore,

and unfortunately it carried quite high rate of restenosis that probably we should start to treat it in the future. Thank you very much for your attention.

- Thanks Fieres. Thank you very much for attending this session and Frank for the invitation. These are my disclosures. We have recently presented the outcomes of the first 250 patients included in this prospective IDE at the AATS meeting in this hotel a few months ago.

In this study, there was no in-hospital mortality, there was one 30-day death. This was a death from a patient that had intracranial hemorrhage from the spinal drain placement that eventually was dismissed to palliative care

and died on postoperative day 22. You also note that there are three patients with paraplegia in this study, one of which actually had a epidural hematoma that was led to various significant and flacid paralysis. That prompted us to review the literature

and alter our outcomes with spinal drainage. This review, which includes over 4700 patients shows that the average rate of complications is 10%, some of those are relatively moderate or minor, but you can see a rate of intracranial hemorrhage of 1.5% and spinal hematoma of 1% in this large review,

which is essentially a retrospective review. We have then audited our IDE patients, 293 consecutive patients treated since 2013. We looked at all their spinal drains, so there were 240 placement of drains in 187 patients. You can see that some of these were first stage procedures

and then the majority of them were the index fenestrated branch procedure and some, a minority were Temporary Aneurysm Sac Perfusions. Our rate of complication was identical to the review, 10% and I want to point out some of the more important complications.

You can see here that intracranial hypotension occurred in 6% of the patients, that included three patients, or 2%, with intracranial hemorrhage and nine patients, or 5%, with severe headache that prolonged hospital stay and required blood patch for management.

There were also six patients with spinal hematomas for a overall rate of 3%, including the patient that I'll further discuss later. And one death, which was attributed to the spinal drain. When we looked at the intracranial hypotension in these 12 patients, you can see

the median duration of headache was four days, it required narcotics in seven patients, blood patch in five patients. All these patients had prolonged hospital stay, in one case, the prolongation of hospital stay was of 10 days.

Intracranial hemorrhage in three patients, including the patient that I already discussed. This patient had a severe intracranial hemorrhage which led to a deep coma. The patient was basically elected by the family to be managed with palliative care.

This patient end up expiring on postoperative day 21. There were other two patients with intracranial hemorrhage, one remote, I don't think that that was necessarily related to the spinal drain, nonetheless we had it on this review. These are some of the CT heads of the patients that had intracranial hemorrhage,

including the patient that passed away, which is outlined in the far left of your slide. Six patients had spinal hematoma, one of these patients was a patient, a young patient treated for chronic dissection. Patient evolved exceptionally well, moving the legs,

drain was removed on postoperative day two. As the patient is standed out of the bed, felt weakness in the legs, we then imaged the spine. You can see here, very severe spinal hematoma. Neurosurgery was consulted, decided to evacuate, the patient woke up with flacid paralysis

which has not recovered. There were two other patients with, another patient with paraplegia which was treated conservatively and improved to paraparesis and continues to improve and two other patients with paraparesis.

That prompted changes in our protocol. We eliminated spinal drains for Extent IVs, we eliminated for chronic dissection, in first stages, on any first stage, and most of the Extent IIIs, we also changed our protocol of drainage

from the routine drainage of a 10 centimeters of water for 15 minutes of the hours to a maximum of 20 mL to a drainage that's now guided by Near Infrared Spectroscopy, changes or symptoms. This is our protocol and I'll illustrate how we used this in one patient.

This is a patient that actually had this actual, exact anatomy. You can see the arch was very difficult, the celiac axis was patent and provided collateral flow an occluded SMA. The right renal artery was chronically occluded.

As we were doing this case the patient experienced severe changes in MEP despite the fact we had flow to the legs, we immediately stopped the procedure with still flow to the aneurysm sac. The patient develops pancreatitis, requires dialysis

and recovers after a few days in the ICU with no neurological change. Then I completed the repair doing a subcostal incision elongating the celiac axis and retrograde axis to this graft to complete the branch was very difficult to from the arm

and the patient recovered with no injury. So, in conclusion, spinal drainage is potentially dangerous even lethal and should be carefully weighted against the potential benefits. I think that our protocol now uses routine drainage for Extent I and IIs,

although I still think there is room for a prospective randomized trial even on this group and selective drainage for Extent IIIs and no drainage for Extent IVs. We use NIRS liberally to guide drainage and we use temporary sac perfusion

in those that have changes in neuromonitoring. Thank you very much.

- Dear Chairman, Ladies and Gentlemen, Thank you Doctor Veith. It's a privilege to be here. So, the story is going to be about Negative Pressure Wound Non-Excisional Treatment from Prosthetic Graft Infection, and to show you that the good results are durable. Nothing to disclose.

Case demonstration: sixty-two year old male with fem-fem crossover PTFE bypass graft, Key infection in the right groin. What we did: open the groin to make the debridement and we see the silergy treat, because the graft is infected with the microbiology specimen

and when identified, the Enterococcus faecalis, Staphylococcus epidermidis. We assess the anastomosis in the graft was good so we decided to put foam, black foam for irrigation, for local installation of antiseptics. This our intention-to treat protocol

at the University hospital, Zurich. Multi-staged Negative Pressure for the Wound Therapy, that's meets vascular graft infection, when we open the wound and we assess the graft, and the vessel anastomosis, if they are at risk or not. If they are not at risk, then we preserve the graft.

If they are at risk and the parts there at risk, we remove these parts and make a local reconstruction. And this is known as Szilagyi and Samson classification, are mainly validated from the peripheral surgery. And it is implemented in 2016 guidelines of American Heart Association.

But what about intracavitary abdominal and thoracic infection? Then other case, sixty-one year old male with intracavitary abdominal infection after EVAR, as you can see, the enhancement behind the aortic wall. What we are doing in that situation,

We're going directly to the procedure that's just making some punctures, CT guided. When we get the specimen microbiological, then start with treatment according to the microbiology findings, and then we downgrade the infection.

You can see the more air in the aneurism, but less infection periaortic, then we schedule the procedure, opening the aneurysm sac, making the complete removal of the thrombus, removing of the infected part of the aneurysm, as Doctor Maelyna said, we try to preserve the graft.

That exactly what we are doing with the white foam and then putting the black foam making the Biofilm breakdown with local installation of antiseptics. In some of these cases we hope it is going to work, and, as you see, after one month

we did not have a good response. The tissue was uneager, so we decided to make the removal of the graft, but, of course, after downgrading of this infection. So, we looked at our data, because from 2012 all the patients with

Prostetic Graft infection we include in the prospective observational cohort, known VASGRA, when we are working into disciplinary with infectious disease specialist, microbiologists, radiologist and surgical pathologist. The study included two group of patients,

One, retrospective, 93 patient from 1999 to 2012, when we started the VASGRA study. And 88 patient from April 2012 to Seventeen within this register. Definitions. Baseline, end of the surgical treatment and outcome end,

the end of microbiological therapy. In total, 181 patient extracavitary, 35, most of them in the groin. Intracavitary abdominal, 102. Intracavitary thoracic, 44. If we are looking in these two groups,

straight with Negative Pressure Wound Therapy and, no, without Negative Pressure Wound Therapy, there is no difference between the groups in the male gender, obesity, comorbidity index, use of endovascular graft in the type Samson classification,

according to classification. The only difference was the ratio of hospitalization. And the most important slide, when we show that we have the trend to faster cure with vascular graft infection in patients with Negative Pressure Wound Therapy

If we want to see exactly in the data we make uni variant, multi variant analysis, as in the initial was the intracavitary abdominal. Initial baseline. We compared all these to these data. Intracavitary abdominal with no Pressure Wound Therapy

and total graft excision. And what we found, that Endovascular indexoperation is not in favor for faster time of cure, but extracavitary Negative Pressure Wound Therapy shows excellent results in sense of preserving and not treating the graft infection.

Having these results faster to cure, we looked for the all cause mortality and the vascular graft infection mortality up to two years, and we did not have found any difference. What is the strength of this study, in total we have two years follow of 87 patients.

So, to conclude, dear Chairman, Ladies and Gentlemen, Explant after downgrading giving better results. Instillation for biofilm breakdown, low mortality, good quality of life and, of course, Endovascular vascular graft infection lower time to heal. Thank you very much for your attention.

(applause)

- So I'm just going to talk a little bit about what's new in our practice with regard to first rib resection. In particular, we've instituted the use of a 30 degree laparoscopic camera at times to better visualize the structures. I will give you a little bit of a update

about our results and then I'll address very briefly some controversies. Dr. Gelbart and Chan from Hong Kong and UCLA have proposed and popularized the use of a 30 degree laparoscopic camera for a better visualization of the structures

and I'll show you some of those pictures. From 2007 on, we've done 125 of these procedures. We always do venography first including intervascular intervention to open up the vein, and then a transaxillary first rib resection, and only do post-operative venography if the vein reclots.

So this is a 19 year old woman who's case I'm going to use to illustrate our approach. She developed acute onset left arm swelling, duplex and venogram demonstrated a collusion of the subclavian axillary veins. Percutaneous mechanical thrombectomy

and then balloon angioplasty were performed with persistent narrowing at the thoracic outlet. So a day later, she was taken to the operating room, a small incision made in the axilla, we air interiorly to avoid injury to the long thoracic nerve.

As soon as you dissect down to the chest wall, you can identify and protect the vein very easily. I start with electrocautery on the peripheral margin of the rib, and use that to start both digital and Matson elevator dissection of the periosteum pleura

off the first rib, and then get around the anterior scalene muscle under direct visualization with a right angle and you can see that the vein and the artery are identified and easily protected. Here's the 30 degree laparoscopic image

of getting around the anterior scalene muscle and performing the electrocautery and you can see the pulsatile vein up here anterior and superficial to the anterior scalene muscle. Here is a right angle around the first rib to make sure there are no structures

including the pleura still attached to it. I always divide, or try to divide, the posterior aspect of the rib first because I feel like then I can manipulate the ribs superiorly and inferiorly, and get the rib shears more anterior for the anterior cut

because that's most important for decompressing the vein. Again, here's the 30 degree laparoscopic view of the rib shears performing first the posterior cut, there and then the anterior cut here. The portion of rib is removed, and you can see both the artery and the vein

are identified and you can confirm that their decompressed. We insufflate with water or saline, and then perform valsalva to make sure that they're hasn't been any pneumothorax, and then after putting a drain in,

I actually also turn the patient supine before extirpating them to make sure that there isn't a pneumothorax on chest x-ray. You can see the Jackson-Pratt drain in the left axilla. One month later, duplex shows a patent vein. So we've had pretty good success with this approach.

23 patients have requires post operative reintervention, but no operative venous reconstruction or bypass has been performed, and 123 out of 125 axillosubclavian veins have been patent by duplex at last follow-up. A brief comment on controversies,

first of all, the surgical approach we continue to believe that a transaxillary approach is cosmetically preferable and just as effective as a paraclavicular or anterior approach, and we have started being more cautious

about postoperative anticoagulation. So we've had three patients in that series that had to go back to the operating room for washout of hematoma, one patient who actually needed a VATS to treat a hemathorax,

and so in recent times we've been more cautious. In fact 39 patients have been discharged only with oral antiplatelet therapy without any plan for definitive therapeutic anticoagulation and those patients have all done very well. Obviously that's contraindicated in some cases

of a preoperative PE, or hematology insistence, or documented hypercoagulability and we've also kind of included that, the incidence of postop thrombosis of the vein requiring reintervention, but a lot of patients we think can be discharged

on just antiplatelets. So again, our approach to this is a transaxillary first rib resection after a venogram and a vascular intervention. We think this cosmetically advantageous. Surgical venous reconstruction has not been required

in any case, and we've incorporated the use of a 30 degree laparoscopic camera for better intraoperative visualization, thanks.

- So I'm going to be talking about allografts for peripheral graft infections. This is a femoral artery that's been replaced after a closure device infection and complication, and we've bypassed to the SFA and profunda femoris. These are my disclosures. So peripheral arterial infectious processes,

well the etiology either is primary or secondary. Primary can be from bacteremic states and seeding of ulcerated plaque or thrombus. Secondary reasons for infections can be the vast usage of percutaneous closure devices that really have flooded the market these days.

Prosthetic graft infections after either a bypass or patch in the femoral artery. So early onset infections usually are from break in sterility. Secondary infections can be from either wound breakdowns or late seeding of the prosthetic graft.

The presentation for these patients can be relatively minor such as cellulitis or draining sinus, or much more dramatic, such as sepsis or pseudoaneurysm or mycotic aneurysm. On the CT scan we can see infected mycotic aneurysm after infected closure device and bleeding complications.

The treatment is broad in range. Ligation is obviously one option, but it leads to a very high risk of major limb amputation. So ideally some form of reconstruction, either extra-anatomic through clean planes,

antibiotic graft as we heard from the previous speaker, the use of autologous replacement with deep vein, or we become big proponents of the use of cryopreserved arterial allografts for reconstruction. And much of this stems from our work from about 10 years ago, where we looked

at the use of aortic cryopreserved grafts for aortic graft infections. This was published about 10 years ago but we looked at a small series of patients with aortic infections. You can see the CT scan of an infected stent graft

and associated aneurysm. And then the intraoperative photo after we've resected the stent graft and replaced that segment of the aorta with a cryopreserved aortic segment. So using that as a springboard,

we then decided to look at the outcomes using these types of conduits, arterial conduits, for peripheral arterial reconstructions in contaminated or infected surgical fields. So retrospective review at our tertiary care center, we looked at roughly 60 patients over a 15-year period

and excluded any aortic-based reconstructions. So these are all peripheral reconstructions. Mean follow-up was 28 months. As you would expect, the distribution of treatment zones were primarily in the lower extremities, so 51 cases.

As you can see, there's a list of all the different types of cases that we treated. But then there were a few upper extremity visceral and then carotid. I've shown this slide before at this meeting in the past, with a carotid patch infection

that was treated after it had a blow-out, and it's obviously a infected aneurysm, and this was treated with resection and a cryopreserved arterial segment. Looking at our outcomes, the 30-day outcome showed a mortality rate of 9%.

The 30-day conduit-related complication rate was surprisingly low at 14%. We had four patients that had bleeding complications, four patients with recurrent infectious complications. All eight of those patients required a return back to the operating room for correction.

The late conduit-related complication rate was only 16%. As listed here, you can see there's only one case of reinfection, three cases of graft thrombosis, surprisingly only one major limb amputation, two pseudoaneurysms and one late bleeding complication.

And graphically depicted, you can see here, this area here is looking at the less than 30 days, this is primarily when the complications occur. When you get to six months, fewer complications, and then beyond six months, the primary complications that we would see are either thrombosis of the graft

or the development of late pseudoaneurysms, again relatively low. So in summary, I think peripheral arterial infectious complications can be treated with a cryopreserved arterial allografts. The advantage is it's a single stage operation,

maintains in-line flow, there's a low incidence of repeat infection. I think it's also important to mention that the majority of these patients had adjunctive muscle flap coverage to cover the large soft tissue defect

at the time of the operation. So I think that this is a valuable alternative conduit in a setting of peripheral arterial infections. Thank you.

- Thank you chairman, ladies and gentlemen. I have no conflict of interest for this talk. So, basically for vTOS we have the well known treatment options. Either the conservative approach with DOAC or anticoagulation for three months or longer supported by elastic stockings.

And alternatively there's the invasive approach with catheter thrombolysis and decompression surgery and as we've just heard in the talk but Ben Jackson, also in surgeons preference, additional PTA and continuation or not of anticoagulation.

And basically the chosen therapy is very much based on the specific specialist where the patient is referred to. Both treatment approaches have their specific complications. Rethrombosis pulmonary embolism,

but especially the post-thrombotic syndrome which is reported in conservative treatment in 26 up to 66%, but also in the invasive treatment approach up to 25%. And of course there are already well known complications related to surgery.

The problem is, with the current evidence, that it's only small retrospective studies. There is no comparative studies and especially no randomized trials. So basically there's a lack of high quality evidence leading to varying guideline recommendations.

And I'm not going through them in detail 'cause it's a rather busy slide. But if you take a quick look then you can see some disparencies between the different guidelines and at some aspects there is no recommendation at all,

or the guidelines refer to selected patients, but they define how they should be selected. So again, the current evidence is insufficient to determine the most clinically and cost effective treatment approach, and we believe that a randomized trial is warranted.

And this is the UTOPIA trial. And I'm going to take you a bit through the design. So the research question underline this trial is, does surgical treatment, consisting of catheter directed thrombolysis and first rib section, significantly reduce post-thrombotic syndrome

occurrence, as compared to conservative therapy with DOAC anticoagulation, in adults with primary upper extremity deep vein thrombosis? The design is multicenter randomized and the population is all adults with first case of primary Upper Extremity

Deep Venous Thrombosis. And our primary outcome is occurrence of post-thrombotic syndrome, and this the find according the modified Villalta score. And there are several secondary outcomes, which of course we will take into account,

such as procedural complications, but also quality of life. This is the trial design. Inclusion informed consent and randomization are performed at first presentation either with the emergency department or outpatient clinic.

When we look at patients 18 years or older and the symptoms should be there for less than 14 days. Exclusion criteria are relevant when there's a secondary upper extremity deep vein thrombosis or any contra-indication for DOACs or catheter directed thrombolysis.

We do perform imaging at baseline with a CT venography. We require this to compare baseline characteristics of both groups to mainly determine what the underlying cause of the thrombosis being either vTOS or idiopathic.

And then a patient follows the course of the trial either the invasive treatment with decompression surgery and thrombolysis and whether or not PTA is required or not, or conservative treatment and we have to prefer DOAC Rivaroxaban or apixaban to be used.

Further down the patient is checked for one month and the Villalta score is adapted for use in the upper extremity and we also apply quality of life scores and scores for cost effectiveness analysis. And this is the complete flowchart of the whole trial.

Again, very busy slide, but just to show you that the patient is followed up at several time points, one, three, six, and 12 months and the 12 months control is actually the endpoint of the trial

And then again, a control CT venography is performed. Sample size and power calculation. We believe that there's an effect size of 20% reduction in post-thrombotic syndrome in favor of the invasive treatment and there's a two-side p-value of 0.05

and at 80% power, we consider that there will be some loss to follow up, and therefore we need just over 150 patients to perform this trial. So, in short, this slide more or less summarize it. It shows the several treatment options

that are available for these patients with Upper Extremity Venous Thrombosis. And in the trial we want to see, make this comparison to see if anticoagulation alone is as best as invasive therapy. I thank for your attention.

So I think when it comes to distal bypasses and ultra-distal bypasses it's all about how we make our decision. We know now that early intervention these patients have better outcome. We use waveform analysis to make our decision about how critical their skin is

we use different topical anesthesia depending the patient's fitness. I think this is just one important point that patient's with dark skin did not show all the full range of skin changes and patients get this dark foot sign

even before they start necrosing their skin. It's very important how we give our anesthetics we use vascular anesthesia with special interest prevascular disease because these patients are quite labile. We use even sometimes inotropes during the procedure

and post operative to maintain a good blood pressure. We believe that short bypasses have got better outcomes. Dr. Veith, have already published in the 80s about short bypasses also doing now the Tibiotibial bypasses on the look anesthetic. Some patients with very high risk for general anesthesia.

And our study we showed that the majority of our patients, who had ultra-distal bypasses had the bypasses from either popliteal or SFA artery. We use different techniques to improve on how to take our bypasses from the proximal anastomosis distally. So we use hybrid revascularization, we use drug-eluting

balloons, and stenting of the SFA and popliteal artery, so we can perform our bypass from the popliteal level. We even use Remote Endarterectomy to improve on our length of the inflow. So by doing remote endarterectomy of the SFA

and popliteal artery, we can take the bypass quite distally from the popliteal artery to the foot level. This is a patient who got critical leg ischaemia on the right side limited, venous conduit. We did remote endarterectomy of her SFA and popliteal artery. And then we can

easily take the bypass from the popliteal artery down to the foot level. On the left side, she had hybrid revascularization with SFA stenting and ultra-distal bypass. We use venous conduit in almost all our patients with ultra-distal bypass.

In distal bypasses we can PTFE but the majority of our patients have long saphenous veins or even arm veins. We started using Omniflow in our infected patients for distal bypasses with quite good results. We scan all our veins prior to the procedure

to make sure that we got good quality vein and amount to perform the procedure. We have published in our small veins series less than 3mm, we still have a very good outcome in distal bypasses. Especially when we do tibial bypasses

or dorsalis pedis bypasses we turn the grafts anatomically. You can see in this angiogram the graft going through the interosseous membrane down to the foot level. We put our incision a bit immediately on the foot level so if there is necrosis of the wound on the foot level that we don't expose the graft, especially when we

knew the patient was coming from the lateral aspect through the interosseous membrane. We select our bypasses especially in the foot level using the duplic scanogram, angiogram or CT angiogram. During the procedure we don't clamp our arteries we use the Flo-Rester and Flo-Through prothesis

to stop patients from bleeding while we're doing it. And we've never used tourniquet before all this has been published. Hand held doppler is the only quality control that we do we don't do on-table angiograms and we find this quite useful for our patients.

We can do the debridement and at the same time while we're doing the bypass at the ankle level. As for anticoagulation and antiplatelet therapy We do antiplatelet therapy for all patient with distal and ultra-distal bypass. And we use heparin and warfarin for patients

who have got redo surgery. Graft surveillance for all our patients Unfortunately, we can only afford it in the NHS for one year, but if the patient get an intervention they go for another full year. Salvage angioplasty is essential for these patients

and we treat these patients as quite as a emergency when they present. So, conclusion, Mr. Sherman, ladies and gentlemen, distal and ultra-distal bypasses require good planning. We use veins for all our bypasses when it comes to the foot level and ultra-distal bypasses,

and of course selecting the target vessel in the foot is very important. Graft Surveillance is essential to maintain quality and outcome for these patients. Thank you very much.

- Thank you Dr. Albaramum, it's a real pleasure to be here and I thank you for being here this early. I have no disclosures. So when everything else fails, we need to convert to open surgery, most of the times this leads to partial endograft removal,

complete removal clearly for infection, and then proximal control and distal control, which is typical in vascular surgery. Here's a 73 year old patient who two years after EVAR had an aneurism growth with what was thought

to be a type II endoleak, had coiling of the infermius mesenteric artery, but the aneurism continued to grow. So he was converted and what we find here is a type III endoleak from sutures in the endograft.

So, this patient had explantations, so it is my preference to have the nordic control with an endovascular technique through the graft where the graft gets punctured and then we put a 16 French Sheath, then we can put a aortic balloon.

And this avoids having to dissect the suprarenal aorta, particularly in devices that have super renal fixation. You can use a fogarty balloon or you can use the pruitt ballon, the advantage of the pruitt balloon is that it's over the wire.

So here's where we removed the device and in spite of the fact that we tried to collapse the super renal stent, you end up with an aortic endarterectomy and a renal endarterectomy which is not a desirable situation.

So, in this instance, it's not what we intend to do is we cut the super renal stent with wire cutters and then removed the struts individually. Here's the completion and preservation of iliac limbs, it's pretty much the norm in all of these cases,

unless they have, they're not well incorporated, it's a lot easier. It's not easy to control these iliac arteries from the inflammatory process that follows the placement of the endograft.

So here's another case where we think we're dealing with a type II endoleak, we do whatever it does for a type II endoleak and you can see here this is a pretty significant endoleak with enlargement of the aneurism.

So this patient gets converted and what's interesting is again, you see a suture hole, and in this case what we did is we just closed the suture hole, 'cause in my mind,

it would be simple to try and realign that graft if the endoleak persisted or recurred, as opposed to trying to remove the entire device. Here's the follow up on that patient, and this patient has remained without an endoleak, and the aneurism we resected

part of the sack, and the aneurism has remained collapsed. So here's another patient who's four years status post EVAR, two years after IMA coiling and what's interesting is when you do delayed,

because the aneurism sacks started to increase, we did delayed use and you see this blush here, and in this cases we know before converting the patient we would reline the graft thinking, that if it's a type III endoleak we can resolve it that way

otherwise then the patient would need conversion. So, how do we avoid the proximal aortic endarterectomy? We'll leave part of the proximal portion of the graft, you can transect the graft. A lot of these grafts can be clamped together with the aorta

and then you do a single anastomosis incorporating the graft and the aorta for the proximal anastomosis. Now here's a patient, 87 years old, had an EVAR,

the aneurism grew from 6 cm to 8.8 cm, he had coil embolization, translumbar injection of glue, we re-lined the endograft and the aneurism kept enlarging. So basically what we find here is a very large type II endoleak,

we actually just clip the vessel and then resected the sack and closed it, did not remove the device. So sometimes you can just preserve the entire device and just take care of the endoleak. Now when we have infection,

then we have to remove the entire device, and one alternative is to use extra-anatomic revascularization. Our preference however is to use cryo-preserved homograft with wide debridement of the infected area. These grafts are relatively easy to remove,

'cause they're not incorporated. On the proximal side you can see that there's a aortic clamp ready to go here, and then we're going to slide it out while we clamp the graft immediately, clamp the aorta immediately after removal.

And here's the reconstruction. Excuse me. For an endograft-duodenal fistula here's a patient that has typical findings, then on endoscopy you can see a little bit of the endograft, and then on an opergy I series

you actually see extravasation from the duodenal. In this case we have the aorta ready to be clamped, you can see the umbilical tape here, and then take down the fistula, and then once the fistula's down

you got to repair the duodenal with an omental patch, and then a cryopreserved reconstruction. Here's a TEVAR conversion, a patient with a contained ruptured mycotic aneurysm, we put an endovascular graft initially, Now in this patient we do the soraconomy

and the other thing we do is, we do circulatory support. I prefer to use ECMO, in this instances we put a very long canula into the right atrium, which you're anesthesiologist can confirm

with transassof forgeoligico. And then we use ECMO for circulatory support. The other thing we're doing now is we're putting antibiotic beads, with specific antibiotic's for the organism that has been cultured.

Here's another case where a very long endograft was removed and in this case, we put the device offline, away from the infected field and then we filled the field with antibiotic beads. So we've done 47 conversions,

12 of them were acute, 35 were chronic, and what's important is the mortality for acute conversion is significant. And at this point the, we avoid acute conversions,

most of those were in the early experience. Thank you.

[Speaker] - Thank you very much and I appreciate the ability to present some of our research. First off, some of this was supported by AHRQ we're going to go through. What's important is, I think, Hyperglycemia is underestimated and It's been shown in general surgery to be a marker of poor clinical outcomes

in a variety of surgical patients. When you look at post-operative Hyperglycemia, it's been studied in general surgery and cardiac surgery. It's been associated with mortality and the surgical site infection. But there really is a limited amount of data

within the vascular information. So, in general, you look at the general surgery, majority of literature shows it has increased risk of infection, it has increased risk of a reoperative surgery, as well as increased risk of death. So we decided we would look at patients

undergoing lower extremity bypasses, open and Endo. And we found that in this study, one in five patients undergoing vascular procedures have hyperglycemia in their postoperative period. And, what was interesting is that diabetes was not an indicator for poor outcomes.

To do this we used the American Association of Endocrinology guidelines, which suggested optimal glucose would be between 80 and 180. Greater than 180 would be considered suboptimal. We then used Cerner information, which is EMR data. We divided the patients between open and endovascular

surgeries. We looked at our glucose targets and we looked at our outcomes. So I think what's most important is we looked at 4,000 patients. Mean years were 67 years in age. But what's more important to actually notice is that hyperglycemia was common,

more common in younger than old. It had an ethnic variability where African-Americans were likely to have hyperglycemia. But still, one in five patients after a lower extremity intervention, open or Endo, had hyperglycemia. So we're really not paying attention to it.

You can see that it occurred in equal percentages within open and endovascular surgery. And when you do a multi-vari logistic regression, we found that hyperglycemia, you had 1.3 times more likely risk of infection during your stay. You have a higher risk length of stay.

You had almost eight times greater risk of death. So, actually what's interesting is that diabetes was found to be productive, which suggests that it's really not diabetes, it's actually hyperglycemia is the main driver. As well, we found that certain medications will increase your hyperglycemia,as well as your disease severity.

We then move through this, we say that one in five patients have hyperglycemia. It's associated with increased lower extremity complications ,increased length of stay, as well as increased mortality. It was actually also unexpected that diabetes was not associated with inferior outcomes

and it's suggested it actually may be a marker with or without diabetic patients. We then looked at hyperglycemia in general surgery patients. We wanted to find out there was a risk in infection, as it's been shown. The general surgery population has thought

that maybe hyperglycemia is the most important risk factor for surgical site infection. We then looked at readmission of patients that underwent lower extremity bypass, to see why they were coming back. We found and infection at the index diagnosis was most significant for having a chance of readmission.

As well as anemia was highly also correlated with readmission. So, infection certainly is an important component to readmission. As well as Hyperglycemia is associated with readmission. It's important to remember that of the patients that come back for readmission after lower extremity procedures, almost half

of the lower extremity bypass procedures were associated with and infectious complication. And finally predictors of readmission, would include Hyperglycemia as it was associated with increased risk of infection at the index study. We then also wanted to see, other patients other studies

have looked to see if it can be controlled. This actually was a nice study, which is a perspective or analyzed study looking at insulin infusion protocol to improve outcomes. They show that surgical site infection was not reduced, they did well to look and see if they could control Hyperglycemia events

with an infrarenal bypass and open surgical repairs. And they used similar metrics for their Optimal Glycemic Control values. This study actually shows which is most interesting, that the most difficult patients to control were the patients with diabetes and the patients undergoing lower extremity bypass.

But they did show that by increasing glucose control, patients had lower rates of, lower lengths of stay. As well as had lower overall costs. So moving along we then looked at AAA. One in six patients who had undergone endovascular repair and open repair of AAA had hyperglycemia.

And we also did not find diabetes reported or predicted for outcome. We found that infections complications were significantly higher if you had postoperative hyperglycemia. Even in endovascular surgery 1.8 times is more likely. We also found diabetes not to be a factor.

So it's obviously more complex than diabetes. Once again mortality was also associated with hyperglycemia after open AAA and endovascular AAA. And we can see again that diabetes was not really playing a role. So AAA, increased mortality is associated with postoperative hyperglycemia.

If you have an EVAR it's 8 times more likely to have mortality. The diabetes was actually somewhat protective. And postoperative hyperglycemia is associated with infectious complications and increased length of stay. There's been suggestion hyperglycemia may be associated with stroke. We looked at this information,

we basically found that the crude rates of stroke were significantly greater for patients with hyperglycemia. We then did a regression analysis to evaluate. We found that stenting actually had a risk of stroke, but hyperglycemia as well also had a higher risk of stroke on this study. And once again diabetes

was not associated. So you can see after hyperglycemia with carotid studies, actually 1 in 7 after elective carotid procedures had hyperglycemia. And they were 8 times more likely to have mortality. 1 point times 7 more likely to have a stroke. So in conclusion, this study actually showed

that you can by involving glycemic control can be managed by using a management service. So you can be improved. This is by Goodney. In conclusion, hyperglycemia is a modifiable event. Postoperative hyperglycemia is very common in vascular surgery population. Between 1 in 5 after lower extremity to 1 in 7 after

elective carotid repair. That actually diabetes was not really the main associated or driver for hyperglycemia. We associate it with infection, length of stay and mortality. And regardless of etiology it can associate with mortality and inferior outcomes. Patients undergoing vascular surgery need

to have hyperglycemic management. And this evidence suggests this may decrease infections as well as complications and mortality. Thank you very much.

- Thank you. Historically, common femoral endarterectomy is a safe procedure. In this quick publication that we did several years ago, showed a 1.5% 30 day mortality rate. Morbidity included 6.3% superficial surgical site infection.

Other major morbidity was pretty low. High-risk patients we identified as those that were functionally dependent, dyspnea, obesity, steroid use, and diabetes. A study from Massachusetts General Hospital their experience showed 100% technical success.

Length of stay was three days. Primary patency of five years at 91% and assisted primary patency at five years 100%. Very little perioperative morbidity and mortality. As you know, open treatment has been the standard of care

over time the goal standard for a common femoral disease, traditionally it's been thought of as a no stent zone. However, there are increased interventions of the common femoral and deep femoral arteries. This is a picture that shows inflection point there.

Why people are concerned about placing stents there. Here's a picture of atherectomy. Irritational atherectomy, the common femoral artery. Here's another image example of a rotational atherectomy, of the common femoral artery.

And here's an image of a stent there, going across the stent there. This is a case I had of potential option for stenting the common femoral artery large (mumbles) of the hematoma from the cardiologist. It was easily fixed

with a 2.5 length BioBond. Which I thought would have very little deformability. (mumbles) was so short in the area there. This is another example of a complete blow out of the common femoral artery. Something that was much better

treated with a stent that I thought over here. What's the data on the stenting of the endovascular of the common femoral arteries interventions? So, there mostly small single centers. What is the retrospective view of 40 cases?

That shows a restenosis rate of 19.5% at 12 months. Revascularization 14.1 % at 12 months. Another one by Dr. Mehta shows restenosis was observed in 20% of the patients and 10% underwent open revision. A case from Dr. Calligaro using cover stents

shows very good primary patency. We sought to use Vascular Quality Initiative to look at endovascular intervention of the common femoral artery. As you can see here, we've identified a thousand patients that have common femoral interventions, with or without,

deep femoral artery interventions. Indications were mostly for claudication. Interventions include three-quarters having angioplasty, 35% having a stent, and 20% almost having atherectomy. Overall technical success was high, a 91%.

Thirty day mortality was exactly the same as in this clip data for open repair 1.6%. Complications were mostly access site hematoma with a low amount distal embolization had previously reported. Single center was up to 4%.

Overall, our freedom for patency or loss or death was 83% at one year. Predicted mostly by tissue loss and case urgency. Re-intervention free survival was 85% at one year, which does notably include stent as independent risk factor for this.

Amputation free survival was 93% at one year, which factors here, but also stent was predictive of amputation. Overall, we concluded that patency is lower than historical common femoral interventions. Mortality was pretty much exactly the same

that has been reported previously. And long term analysis is needed to access durability. There's also a study from France looking at randomizing stenting versus open repair of the common femoral artery. And who needs to get through it quickly?

More or less it showed no difference in outcomes. No different in AVIs. Higher morbidity in the open group most (mumbles) superficial surgical wound infections and (mumbles). The one thing that has hit in the text of the article

a group of mostly (mumbles) was one patient had a major amputation despite having a patent common femoral artery stent. There's no real follow up this, no details of this, I would just caution of both this and VQI paper showing increased risk amputation with stenting.

Thank you.

- My topic is status of left atrial appendage exclusion and we're going to go to the heart in this topic. This is my disclosures: atricure being the main one. The other disclosure is we actually have an annual meeting of left atrial appendage that takes over three days, so this is a very

extensive topic and I'm going to ask you to put your seat belts on because it's going to be a lot of topics to cover over five minutes. So, as you know, the left atrial appendage is the source of thrombus that comes from the heart in ninety percent of patients so patients

who have a stroke coming from the heart, ninety percent chances are the clot was in the left atrial appendage. If you look at just in the US, if we can take care of left atrial appendage in these patients, we can deal with 130,000 strokes.

It's a very substantial number. And this translates with the amount of money that the industry has put in this. Over half a billion dollars currently and it's increasing significantly. This is one of the fastest growing area

of devices worldwide in any specialty. Now left atrial appendage also excludes atrial fibrillation so besides dropping and reducing the stroke, it does also an electric isolation so it reduces the atrial fibrillation rate in patients

who have chronic AFIB so those are two main reasons why we close left atrial appendage in specific patients who have the indication for. Now I'm going to go over the talk if you look at patients who have an open heart surgery, they already know, based upon this recently

published journal publication from Mayo Clinic, that left atrial exclusion significantly reduces stroke. In these patients, they actually look at 75,000 patients, five percent of them had surgical exclusion and that that propensity analysis among patients who had AFIB and closure of appendage versus

the same patient population with similar risk who did not and they had significantly less stroke in patients who had exclusion of appendage, as you see here, and less mortality. There is a specific trial called ATLAS that is going to be given a more randomized study

but there is a lot of data already supporting that appendage reduces significant stroke. Now these are the two studies. This is one of the most important slides that I want you to remember. They are the Endocardial Trial Devices

and there are Epicardial Devices and I'm going to go over in the last slide what are the pros and cons of each one. What I'm going to talk about each of them at a time. Now endocardial is obviously transcatheter techniques. Epicardial is a clip that is typically placed

outside but it could be also endocardial, as well. So Watchman is the most common device that is placed endocardial. It's also the only one that is FDA approved currently. And it's probably the best device that we will place in an elderly patients or failed patients.

It's 14 Fringe, has five sizes based upon a CT Scan. Sized pretty much like a anthracic aneurysm in how we measure actually, triple As. It's sized 10 o

and has 10 barbs in it. It's also approved in CE marks, as well. Now the FLX version of it is a new version that has been overworked right now but this study, this device is actually the most studied device. Protect-AF and Prevails are the typical two studies

and they have shown at four-year followup that the ischemic stroke and systemic embolization is significantly lower and comparable to coumadin and significantly lower bleeding rate, as well. But they are not perfect obviously. There is a lot of patients that cannot be treated

due to anatomic issues. There is also percent of patients will have leaks that will require additional anticoagulation. Now Amplatzer is not approved.

It's not a percutaneous endocardial device, that is CE marked, but I'm not going to spend time just because of the timing. Same applies to WaveCrest, Occulotech, and LAmbre. You can imagine these at the early time of EVARS and TVARS that we have initially one device on the market

and now more and more devices coming up. We have a similar one on the left atrial appendage. And these devices will come into market within the next few years. They are already in Europe available. But no randomized trials.

Now with all these endocardial devices there are multiple leak effects typically including leaking around it because as you know appendage orifices is not a perfect circle. It's not like a aorta, many aortas, at least. You could have an area that is very narrowed

and you could have what we call a really perivalval leak which cardiologists will name differently, a agofact in this case. Now one of the epicardial devices, these are devices that come from outside, is called the LARIAT.

This is 510K approved in the United States and also available in CE but has significant complications. Why? Because it's an endocardial device. That means you have to transvenous access and have a transeptal from right atrium going to the left atrium but also you have

to access the pericardium and pretty much put a loop around the left atrial appendage that connects over a magnet. It's actually a pretty neat device but it has significant issues with complications including tamponade and its the only device

that has actually a death rather compared to any other ones. Other ones have almost zero mortality rates. There is a leak option so if you close that appendage with a circular device, if you continues to have some blood going into it

this enlargened sac can actually open up again to orifices that's called the Gunnysack Effect. And one of the issues that, you know, Lariat has a failure rate. Plus, Lariat can be only applied for certain sizes of appendages that are small,

so that's important, as well. Now there are a lot of issues with surgical closures. I'm going to shorten this portion but to say the suture alone is not a perfect idea and for that reason, we actually use a clip for this that's called the AtriClip

that is FDA approved and this is how it looks like from inside the heart. You have an endocardial to endocardial apposition with less thrombogenesty. This is the AtroClip device again and we have option also to put that as a

thoracoscopic approach for patients who do not need open heart surgery. As you see at three month, the entire appendage dies off from ischemic event: it goes away, which is what we want. This is the prospective trial that showed

the safety of this device. And this is the left atrial appendage symposium that I mentioned to you. If you look at the Watchman device, the leak is a certain concern but it's the safest device for elderly patients, however, the epicardial

device are the safest with the lowest rate of leak and best outcome. Overall, this is my last slide, I think 100 percent of closing the left atrial appendage is important so that's the reason epicardial device right now are much more successful.

This is an important concept for patient with permanent AFib: it can cut down on the stroke risk by 90 percent and improves survival in patients and loved ones who has atrial fibrillation. Efficacy has been shown in multiple studies and in the safety, as well (mumbles).

If we have a heart-team approach, very similar like in the vascular approach, I think it takes away the specialty bias among the two various closure devices. Thank you very much.

- Thank you very much for the kind introduction, and I'd like to thank the organizers, especially Frank Veith for getting back to this outstanding and very important conference. My duty is now to talk about the acute status of carotid artery stenting is acute occlusion an issue? Here are my disclosures.

Probably you might be aware, for sure you're aware about pore size and probably smaller pore size, the small material load might be a predisposing factor for enhanced thrombogenicity in these dual layer stents, as you're probably quite familiar with the CGUARD, Roadsaver and GORE, I will focus my talk a little bit

on the Roadsaver stent, since I have the most experience with the Roadsaver stent from the early beginning when this device was on the market in Europe. If you go back a little bit and look at the early publications of CGUARD, Roadsaver and GORE stent, then acute occlusion the early reports show that

very clearly safety, especially at 30 days in terms of major cardiac and cerebrovascular events. They are very, very safe, 0% in all these early publications deal with these stents. But you're probably aware of this publication, released end of last year, where a German group in Hamburg

deals with carotid artery stenosis during acute stroke treatment. They used the dual layer stent, the Roadsaver stent or the Casper stent in 20 cases, in the same time period from 2011 to 2016, they used also the Wallstent and the VIVEXX stent,

in 27 cases in total and there was a major difference, in terms of acute stent occlusion, and for the Roadsaver or Casper stent, it was 45%, they also had an explanation for that, potential explanations probably due to the increase of thrombogenic material due to the dual layer

insufficient preparation with antiplatelet medication, higher patient counts in the patients who occluded, smaller stent diameters, and the patients were not administered PTA, meaning Bridging during acute stroke patient treatment, but it was highlighted that all patients received ASA of 500mg intravenously

during the procedure. But there are some questions coming up. What is a small stent diameter? Post-dilatation at what diameter, once the stent was implanted? What about wall apposition of the stent?

Correct stent deployment with the Vicis maneuver performed or not and was the ACT adjusted during the procedure, meaning did they perform an adequate heparinization? These are open questions and I would like to share our experience from Flensburg,

so we have treated nearly 200 patients with the Roadsaver stent from 2015 until now. In 42 patients, we used this stent exclusively for acute stroke treatment and never, ever observed in both groups, in the symptomatic and asymptomatic group and in the group of acute stroke treatment,

we never observed an acute occlusion. How can we explain this kind of difference that neither acute occlusion occurred in our patient group? Probably there are some options how we can avoid stent thrombosis, how we can minimize this. For emergency treatment, probably this might be related

to bridging therapies, though in Germany a lot of patients who received acute stroke treatment are on bridging therapy since the way to the hospital is sometimes rather long, there probably might be a predisposing factor to re-avoid stent thrombosis and so-called tandem lesions if the stent placement is needed.

But we also take care of antiplatelet medication peri-procedurally, and we do this with ASA, as the Hamburg group did and at one day, we always start, in all emergency patients with clopidogrel loading dose after positive CT where we could exclude any bleeding and post-procedurally we go

for dual anti-platelet therapy for at least six months, meaning clopidogrel and ASA, and this is something probably of utmost importance. It's quite the same for elective patients, I think you're quite familiar with this, and I want to highlight the post-procedural clopidogrel

might be the key of success for six months combined with ASA life-long. Stent preparation is also an issue, at least 7 or 8 diameters we have to choose for the correct lengths we have to perform adequate stent deployment and adequate post-dilatation

for at least 5mm. In a lot of trials the Roadsaver concept has been proven, and this is due to the adequate preparation of the stent and ongoing platelet preparation, and this was also highlight in the meta-analysis with the death and stroke rate of .02% in all cases.

Roadsaver study is performed now planned, I am a member of the steering committee. In 2000 patients, so far 132 patients have been included and I want to rise up once again the question, is acute occlusion and issue? No, I don't think so, since you keep antiplatelet medication

in mind and be aware of adequate stent sizing. I highly appreciated your attention, thank you very much.

- We are talking about the current management of bleeding hemodialysis fistulas. I have no relevant disclosures. And as we can see there with bleeding fistulas, they can occur, you can imagine that the patient is getting access three times a week so ulcerations can't develop

and if they are not checked, the scab falls out and you get subsequent bleeding that can be fatal and lead to some significant morbidity. So fatal vascular access hemorrhage. What are the causes? So number one is thinking about

the excessive anticoagulation during dialysis, specifically Heparin during the dialysis circuit as well as with cumin and Xarelto. Intentional patient manipulati we always think of that when they move,

the needles can come out and then you get subsequent bleeding. But more specifically for us, we look at more the compromising integrity of the vascular access. Looking at stenosis, thrombosis, ulceration and infection. Ellingson and others in 2012 looked at the experience

in the US specifically in Maryland. Between the years of 2000/2006, they had a total of sixteen hundred roughly dialysis death, due to fatal vascular access hemorrhage, which only accounted for about .4% of all HD or hemodialysis death but the majority did come

from AV grafts less so from central venous catheters. But interestingly that around 78% really had this hemorrhage at home so it wasn't really done or they had experienced this at the dialysis centers. At the New Zealand experience and Australia, they had over a 14 year period which

they reviewed their fatal vascular access hemorrhage and what was interesting to see that around four weeks there was an inciting infection preceding the actual event. That was more than half the patients there. There was some other patients who had decoags and revisional surgery prior to the inciting event.

So can the access be salvaged. Well, the first thing obviously is direct pressure. Try to avoid tourniquet specifically for the patients at home. If they are in the emergency department, there is obviously something that can be done.

Just to decrease the morbidity that might be associated with potential limb loss. Suture repairs is kind of the main stay when you have a patient in the emergency department. And then depending on that, you decide to go to the operating room.

Perera and others 2013 and this is an emergency department review and emergency medicine, they use cyanoacrylate to control the bleeding for very small ulcerations. They had around 10 patients and they said that they had pretty good results.

But they did not look at the long term patency of these fistulas or recurrence. An interesting way to kind of manage an ulcerated bleeding fistula is the Limberg skin flap by Pirozzi and others in 2013 where they used an adjacent skin flap, a rhomboid skin flap

and they would get that approximal distal vascular control, rotate the flap over the ulcerated lesion after excising and repairing the venotomy and doing the closure. This was limited to only ulcerations that were less than 20mm.

When you look at the results, they have around 25 AV fistulas, around 15 AV grafts. The majority of the patients were treated with percutaneous angioplasty at least within a week of surgery. Within a month, their primary patency was running 96% for those fistulas and around 80% for AV grafts.

If you look at the six months patency, 76% were still opened and the fistula group and around 40% in the AV grafts. But interesting, you would think that rotating an adjacent skin flap may lead to necrosis but they had very little necrosis

of those flaps. Inui and others at the UC San Diego looked at their experience at dialysis access hemorrhage, they had a total 26 patients, interesting the majority of those patients were AV grafts patients that had either bovine graft

or PTFE and then aneurysmal fistulas being the rest. 18 were actually seen in the ED with active bleeding and were suture control. A minor amount of patients that did require tourniquet for a shock. This is kind of the algorithm when they look at

how they approach it, you know, obviously secure your proximal di they would do a Duplex ultrasound in the OR to assess hat type of procedure

they were going to do. You know, there were inciting events were always infection so they were very concerned by that. And they would obviously excise out the skin lesion and if they needed interposition graft replacement they would use a Rifampin soak PTFE

as well as Acuseal for immediate cannulation. Irrigation of the infected site were also done and using an impregnated antibiotic Vitagel was also done for the PTFE grafts. They were really successful in salvaging these fistulas and grafts at 85% success rate with 19 interposition

a patency was around 14 months for these patients. At UCS, my kind of approach to dealing with these ulcerated fistulas. Specifically if they bleed is to use

the bovine carotid artery graft. There's a paper that'll be coming out next month in JVS, but we looked at just in general our experience with aneurysmal and primary fistula creation with an AV with the carotid graft and we tried to approach these with early access so imagine with

a bleeding patient, you try to avoid using catheter if possible and placing the Artegraft gives us an opportunity to do that and with our data, there was no significant difference in the patency between early access and the standardized view of ten days on the Artegraft.

Prevention of the Fatal Vascular Access Hemorrhages. Important physical exam on a routine basis by the dialysis centers is imperative. If there is any scabbing or frank infection they should notify the surgeon immediately. Button Hole technique should be abandoned

even though it might be easier for the patient and decreased pain, it does increase infection because of that tract The rope ladder technique is more preferred way to avoid this. In the KDOQI guidelines of how else can we prevent this,

well, we know that aneurysmal fistulas can ulcerate so we look for any skin that might be compromised, we look for any risk of rupture of these aneurysms which rarely occur but it still needs to taken care of. Pseudoaneurysms we look at the diameter if it's twice the area of the graft.

If there is any difficulty in achieving hemostasis and then any obviously spontaneous bleeding from the sites. And the endovascular approach would be to put a stent graft across the pseudoaneurysms. Shah and others in 2012 had 100% immediate technical success They were able to have immediate access to the fistula

but they did have around 18.5% failure rate due to infection and thrombosis. So in conclusion, bleeding to hemodialysis access is rarely fatal but there are various ways to salvage this and we tried to keep the access viable for these patients.

Prevention is vital and educating our patients and dialysis centers is key. Thank you.

- Thank you Mr. Chairman, thank you Dr. Veith for the kind invitation. I have no disclosures relevant to this particular lecture. But I think we ought to talk about what critical limb ischemia is. Obviously it's what we call Rutherford four through six. It's most commonly associated with multi-level disease.

About 1/3 or so of the cases are infrapopliteal only, mostly in diabetic patients. There's very poor overall life expectancies. We look at this group of patients in multiple studies, it ranges somewhere between three and four years of average life expectancy,

and there are substantial differences in outcomes within critical limb ischemia, with far worse outcomes in those with poor overall health, advanced stage presentation, or poor runoff at the level of the foot. Now, what is the rationale for endovascular therapy

in critical limb ischemia? Well first, patients are often old and infirmed, and many aren't really considered candidates for open surgery because of poor overall health. Surgery requires inflow, usually attainable. Outflow, not always so easy.

A conduit, which typically should be vein, if we want durable results, and an incision. Active infection is problematic, as there may be graft infection or sepsis. Extensive surgical scarring may compromise future rescue intervention,

and this is a progressive disease, that often requires additional treatment. Now, there have been multiple publications, and this is just a recent one, which came out in the Journal of the American Heart Association. It's a multidisciplinary,

retrospective analysis of Medicare data in people who had presented with critical limb ischemia. This is not perspective, it's not sited in many areas, but I ask you to look at this conclusion. It was there was lower major amputation rates following endovascular therapy.

Both surgery and endovascular did better than primary amputation, in terms of outcomes. But again, this is not a perfect study. Now, we have many publications which have shown very good limb salvage rates in patients using interventions.

Here we see this from Faglia, again showing very low major amputation rates. This from Sam Ahn, once again, very good limb salvage rates. But in truth, we have only one randomized, control trial, level one data, comparing intervention with surgery. And that was the BASIL Trial.

The BASIL Trial is an old trial, it's criticized, appropriately, because the only treatment used was sub-intimal angioplasty. And with sub-intimal angioplasty, often, the sub-intimal tract in crossing is far greater than the area of total occlusion,

resulting in much longer treatment zones. In addition, this trial did not allow some of the new and better treatments that are now available for having better patency to be performed. Nonetheless, in the BASIL Trial, despite very primitive treatment,

that being only sub-intimal angioplasty, we can see that one year out, and in fact out to two years, angioplasty and surgery were relatively equal in terms of limb salvage. At five years, there seemed to be a major advantage to surgery,

in terms of both quality of life, and in terms of less need for reintervention. So then we have to ask, what has changed since BASIL? Well now we have far better crossing. We have re-entry tools that stop us from having to go 10 centimeters

beyond the area of occlusion to get back in. Dedicated crossing tools, better wires, retrograde access, this is important, we have markedly improved patency, with drug coated balloons, drug-eluting stents, wire interwoven nitinol stents, and stent grafts, which have shown in the SFA all of these things,

better SFA patency, and if indeed, we can maintain SFA patency in multi-level disease, often, if there's recurrence, the patients do well. We also have improved Tibial patency in the proximal tibial vessels. However, we do not yet have a great endovascular solution

for long distal tibial vessel occlusions, and that's just the truth. I have to go back here, one, but we have better medical therapy too. As we look at PCSK9 inhibitors, in the GLAGOV Trial, we see in other parts of the body,

a 30% reduction in atherosclerotic volume out at 70 weeks, indeed will this change what we're doing. This has launched this decade of endovascular interventions. So what about this taking away surgical options? BASIL, I think, doesn't apply because the sections went far beyond where they should.

That's bad technique. Stenting across the common femoral or patent popliteal, in my opinion, bad technique. Distal embolization, we've not done enough preparation. I will also caution that sometimes, surgery has bad outcomes as well.

So, the rationale is we really don't want to perform anything that hurts a patient. Entire procedures performed via a sheath, remote from the site, there's less pain, shorter recovery, no extensive scar, and the argument that intervention

takes away surgical options, I think is no longer so valid. Bad intervention or bad surgery, take away options. Where is distal bypass indicated? In large non-healing ulcers in patients with good life expectancy, good quality vein, good outflow, and excellent surgical expertise.

Densely calcified long segment infrapopliteal disease, or disease from the common femoral all the way to the ankle. I think these clearly are going to do better with surgery, certainly in today's world. But even these areas may change. If more effective tools solve the patency problems,

with long segment infrapopliteal disease, and there are trials now aiming at this, such as SAVAL, DCB trials, and Lithoplasty. I thank you for your attention.

- Thank you very much and thank you Dr. Veith for the kind invite. Here's my disclosures, clearly relevant to this talk. So we know that after EVAR, it's around the 20% aortic complication rate after five years in treating type one and three Endoleaks prevents subsequent

secondary aortic rupture. Surveillance after EVAR is therefore mandatory. But it's possible that device-specific outcomes and surveillance protocols may improve the durability of EVAR over time. You're all familiar with this graph for 15 year results

in terms of re-intervention from the EVAR-1 trials. Whether you look at all cause and all re-interventions or life threatening re-interventions, at any time point, EVAR fares worse than open repair. But we know that the risk of re-intervention is different

in different patients. And if you combine pre-operative risk factors in terms of demographics and morphology, things are happening during the operations such as the use of adjuncts,

or having to treat intro-operative endoleak, and what happens to the aortic sac post-operatively, you can come up with a risk-prediction tool for how patients fare in the longer term. So the LEAR model was developed on the Engage Registry and validated on some post-market registries,

PAS, IDE, and the trials in France. And this gives a predictive risk model. Essentially, this combines patients into a low risk group that would have standard surveillance, and a higher risk group, that would have a surveillance plus

or enhanced surveillanced model. And you get individual patient-specific risk profiles. This is a patient with around a seven centimeter aneurysm at the time of repair that shows sac shrinkage over the first year and a half, post-operatively. And you can see that there's really a very low risk

of re-intervention out to five years. These little arrow bars up here. For a patient that has good pre-operative morphology and whose aneurysm shrinks out to a year, they're going to have a very low risk of re-intervention. This patient, conversely, had a smaller aneurysm,

but it grew from the time of the operation, and out to two and a half years, it's about a centimeter increase in the sac. And they're going to have a much higher risk of re-intervention and probably don't need the same level of surveillance as the first patient.

and probably need a much higher rate of surveillance. So not only can we have individualized predictors of risk for patients, but this is the regulatory aspect to it as well.

Multiple scenario testing can be undertaken. And these are improved not only with the pre-operative data, but as you've seen with one-year data, and this can tie in with IFU development and also for advising policy such as NICE, which you'll have heard a lot about during the conference.

So this is just one example. If you take a patient with a sixty-five millimeter aneurysm, eighteen millimeter iliac, and the suprarenal angle at sixty degrees. If you breach two or more of these factors in red, we have the pre-operative prediction.

Around 20% of cases will be in the high risk group. The high risk patients have about a 50-55% freedom from device for related problems at five years. And the low risk group, so if you don't breach those groups, 75% chance of freedom from intervention.

In the green, if you then add in a stent at one year, you can see that still around 20% of patients remain in the high risk group. But in the low risk group, you now have 85% of patients won't need a re-intervention at five years,

and less of a movement in the high risk group. So this can clearly inform IFU. And here you see the Kaplan-Meier curves, those same groups based pre-operatively, and at one year. In conclusion, LEAR can provide

a device specific estimation of EVAR outcome out to five years. It can be based on pre-operative variables alone by one year. Duplex surveillance helps predict risk. It's clearly of regulatory interest in the outcomes of EVAR.

And an E-portal is being developed for dissemination. Thank you very much.

- Good morning. Thank you for the opportunity to speak. So thirty day mortality following unselected non-cardiac surgery in patients 45 years and older has been reported to be as high as 1.9%. And in such patients we know that postoperative troponin elevation has

a very strong correlation with 30-day mortality. Considering that there are millions of major surgical procedures performed, it's clear that this equates to a significant health problem. And therefore, the accurate identification of patients at risk of complications

and morbidity offers many advantages. First, both the patient and the physician can perform an appropriate risk-benefit analysis based on the expected surgical benefit in relation to surgical risk. And surgery can then be declined,

deferred, or modified to maximize the patient's benefit. Secondly, pre-operative identification of high-risk patients allows physicians to direct their efforts towards those who might really benefit from additional interventions. And finally, postoperative management,

monitoring and potential therapies can be individualized according to predicted risk. So there's a lot of data on this and I'll try to go through the data on predictive biomarkers in different groups of vascular surgery patients. This study published in the "American Heart Journal"

in 2018 measured troponin levels in a prospective blinded fashion in 1000 patients undergoing non-cardiac surgery. Major cardiac complications occurred overall in 11% but in 24% of the patients who were having vascular surgery procedures.

You can see here that among vascular surgery patients there was a really high prevalence of elevated troponin levels preoperatively. And again, if you look here at the morbidity in vascular surgery patients 24% had major cardiac complications,

the majority of these were myocardial infarctions. Among patients undergoing vascular surgery, preoperative troponin elevation was an independent predictor of cardiac complications with an odds ratio of 1.5, and there was an increased accuracy of this parameter

in vascular surgery as opposed to non-vascular surgery patients. So what about patients undergoing open vascular surgery procedures? This is a prospective study of 455 patients and elevated preoperative troponin level

and a perioperative increase were both independently associated with MACE. You can see here these patients were undergoing a variety of open procedures including aortic, carotid, and peripheral arterial. And you can see here that in any way you look at this,

both the preoperative troponin, the postoperative troponin, the absolute change, and the relative change were all highly associated with MACE. You could add the troponin levels to the RCRI a clinical risk stratification tool and know that this increased the accuracy.

And this is additionally shown here in these receiver operator curves. So this study concluded that a combination of the RCRI with troponin levels can improve the predictive accuracy and therefore allow for better patient management.

This doesn't just happen in open-vascular surgery patients. This is a study that studied troponin levels in acute limb ischaemia patients undergoing endovascular therapy. 254 patients all treated with endovascular intervention

with a 3.9% mortality and a 5.1% amputation rate. Patients who died or required amputation more frequently presented with elevated troponin levels. And the relationship between troponin and worse in-hospital outcome remains significant even when controlling for other factors.

In-hospital death or amputation again and amputation free survival were highly correlated with preoperative troponin levels. You can see here 16.9% in patients with elevated troponins versus 6% in others. And the cardiac troponin level

had a high hazard ratio for predicting worse in-hospital outcomes. This is a study of troponins just in CLI patients with a similar design the measurement of troponin on admission again was a significant independent predictor

of survival with a hazard ratio of 4.2. You can see here that the majority of deaths that did occur were in fact cardiac, and troponin levels correlated highly with both cardiac specific and all-cause mortality. The value of the troponin test was maintained

even when controlling for other risk factors. And these authors felt that the realistic awareness of likely long term prognosis of vascular surgery patients is invaluable when planning suitability for either surgical or endovascular intervention.

And finally, we even have data on the value of preoperative troponin in patients undergoing major amputation. This was a study in which 10 of 44 patients had a non-fatal MI or died from a cardiac cause following amputation.

A rise in the preoperative troponin level was associated with a very poor outcome and was the only significant predictor of postoperative cardiac events. As you can see in this slide. This clearly may be a "Pandora's box".

We really don't know who should have preoperative troponins. What is the cost effectiveness in screening everybody? And in patients with elevated troponin levels, what exactly do we do? Do we cancel surgery, defer it, or change our plan?

However, certainly as vascular surgeons with our high-risk patient population we believe in risk stratification tools. And the RCRI is routinely used as a clinical risk stratification tool. Adding preoperative troponin levels to the RCRI

clearly increases its accuracy in the prediction of patients who will have perioperative cardiac morbidity or mortality. And you can see here that the preoperative troponin level had one of the highest independent hazard ratios at 5.4. Thank you very much for your attention.

- Thank you very much indeed and thank you again, Frank. The European Society guidelines, just to get things put surely, if you've had a major stroke and a large infarction with altered consciousness and drowsiness we recommend that surgery should be deferred and should not be urgently entered.

Similarly patients who present with stroke and evolution or crescendo TIAs are a very special subgroup, relatively small, and these should be treated with carotid surgery within 24 hours. So that gets rid of the two questions that somebody's going to ask afterwards.

What we're dealing with is how should you treat the non-disabling stroke or TIA. Now this is the natural history of early recurrent stroke after a TIA in patients with 50 to 99% stenoses and you can see that the early risks are really very high indeed, way higher than was reported

in the randomized trials. And that was because these patients never were included in the randomized trials. They'd suffered their stroke long before they had a chance to be treated. And we know from a meta-analysis of the pooled ECST,

NASCET, and VA data that the quicker you offer surgery the more strokes that you prevent in the long term, particularly in patients with severe stenoses. And so for that reason the ESVS recommended that wherever possible patients who have presented with a TIA or a non-disabling stroke,

they should undergo a carotid intervention within 14 days of onset, preferably as soon as possible. Now there's a lot of debate about the impact of if you operate early does that increase the procedural risk? Well there have been three big registries,

the Swedish with two and a half thousand patients, the UK with 23,000, and the German with 56,000. The study that captures eternal attention is the Swedish study with the 11% death and stroke rate within 48 hours. But while there was a small but modest increase

in the 48 hours complication rates with the UK and German databases, there were nowhere near as gross as the Swedish ones. The reality is it's quite difficult to get somebody with a non-disabling stroke into the operating theater within 48 hours.

The problem is in terms of whether you should do stenting or surgery is that the overviews of the randomized trials have shown that stenting is still associated with a threefold excess risk if you perform surgery within either seven days or eight to 14 days.

So the European Society recommended that if you are undergoing revascularization within the first 14 days it's preferable to offer carotid endarterectomy rather than carotid stenting, but as I will mention later, that might change

the next time the guidelines are published. And we also concluded that if you have, you do have comorbidities in recently symptomatic patients who make them high risk for surgery, and these are going to be careful about the definition of that. We recommend that an MDT needs to review that decision,

but if that is the case then stenting should be considered as an alternative. Now, I thought it useful also to point out that we recommend that early endarterectomy within 14 days should be considered after intravenous thrombolysis.

If the patient makes a rapid recovery the area of infarction is less than one-third of the MCA territory, a previously occluded middle cerebral mainstem is recanalized, and there is a significant stenosis and no evidence of any parenchymal hemorrhage

or significant brain edema. Now there is a careful caveat to this, and that is that you should withhold IV heparin and antiplatelet therapy for 24 hours after lysis completion, but then before you take the patient to theater

the patient should be restarted on antiplatelet therapy. So that will introduce a small delay, but if you don't the risks of hemorrhage are much higher. There are unanswered questions of course that the guidelines that Jean Baptiste and I chaired cannot answer.

First of all, do newer CAS technologies mean that it can be performed as safely as endarterectomy in the first seven to 14 days. And I'm notably referring to TCAR. Now I know there's a very large registry being published on the results of TCAR,

and I've reviewed it for the Journal of Vascular Surgery. And I heard Glenn Darling present it to the European meeting. But they cannot tell you what the death and stroke rates were when operations were performed within seven or 14 days of surgery,

and this is crucial. There's no point in saying that TCAR's fantastically good in asymptomatic patients or patients whose symptoms were three months ago. What we need to know is whether this offers a benefit in patients within the first seven to 14 days.

And the other big issue is whether following mechanical thrombectomy should a tandem internal carotid artery stenosis be treated by synchronous stenting or by deferred stenting to surgery. Now I was reviewing a lot of the literature

for a separate presentation yesterday, and the jury is out on that because there is not much published. But there do seem to be increased hemorrhagic complication rates where you have patients who undergo a synchronous mechanical thrombectomy

and synchronous carotid stenting. Thank you very much.

- Thank you very much and I would like to thank Dr. Veit for the kind invitation, this is really great meeting. Those are my disclosures. Percutaneous EVAR has been first reported in the late 1990's. However, for many reasons it has not been embraced

by the vascular community, despite the fact that it has been shown that the procedure can be done under local anesthesia and it decreases OR time, time to ambulation, wound complication and length of stay. There are three landmark papers which actually change this trend and make PEVAR more popular.

All of these three papers concluded that failure or observed failure of PEVAR are observed and addressed in the OR which is a key issue. And there was no late failures. Another paper which is really very prominent

is a prospective randomize study that's reported by Endologix and published in 2014. Which revealed that PEVAR closure of the arteriotomy is not inferior to open cut down. Basically, this paper also made it possible for the FDA to approve the device, the ProGlide device,

for closure of large bore arteriotomies, up to 26 in the arterial system and 29 in the venous system. We introduced percutaneous access first policy in our institution 2012. And recently we analyzed our results of 272 elective EVAR performed during the 2012 to 2016.

And we attempted PEVAR in 206 cases. And were successful in 92% of cases. But the question was what happened with the patient that failed PEVAR? And what we found that was significantly higher thrombosis, vessel thrombosis,

as well as blood loss, more than 500 cc in the failed PEVAR group. Similarly, there was longer operative time and post-operative length of stay was significantly longer. However, in this relatively small group of patients who we scheduled for cut-down due to different reasons,

we found that actually there was no difference between the PEVAR and the cut-down, failed PEVAR and cut-down in the terms of blood loss, thrombosis of the vessel, operative time and post-operative length of stay. So what are the predictors of ProGlide failure?

Small vessel calcification, particularly anterior wall calcification, prior cut-down and scarring of the groin, high femoral bifurcation and use of large bore sheaths, as well as morbid obesity. So how can we avoid failures?

I think that the key issue is access. So we recommend that all access now or we demand from our fellow that when we're going to do the operation with them, cut-down during fluoroscopy on the ultra-sound guidance, using micropuncture kits and access angiogram is actually mandatory.

But what happened when there is a lack of hemostasis once we've deployed two PEVARs? Number one, we try not to use more than three ProGlide on each side. Once the three ProGlide failed we use the angioseal. There's a new technique that we can have body wire

and deployed angioseal and still have an access. We also developed a technique that we pack the access site routinely with gelfoam and thrombin. And also we use so-called pull and clamp technique, shown here. Basically what it is, we pull the string of the ProGlide

and clamp it on the skin level. This is actually a very very very good technique. So in conclusion, PEVAR first approach strategy successful in more than 90% of cases, reduced operative time and postoperative length of stay, the failure occurred more commonly when the PEVAR

was completed outside of IFU, and there was no differences in outcome between failed PEVAR and planned femoral cut-down. Thank you.

- So PAD affects five million adults in the United States today, and we know the US population is aging. And 15 to 20% of folks 70 years and older have claudication, a minority of these progress to CLI, and the impact on lifestyle is often minimized, as demonstrated in decreased quality of life scores

in these patients. Now with active tobacco use, there is acceleration of disease towards claudication, and there are higher rates of amputation, MI, and death. But prior to open or endo intervention, the SVS Guidelines recommend supervised exercise,

medical therapy with statins, beta blockers, antiantiplatelets, and Cilostazol, and an aggressive multidisciplinary approach to smoking cessation, which should last no less than six months. But what if a patient can't stop smoking?

We've all had these patients. Should patients with lifestyle limiting claudication be denied open surgical or endo-revascularization? So let's look at the open literature. A meta-analysis performed in 2005 of 29 eligible studies. The results were that bypass graft failure

was three times that in smokers versus nonsmokers. There was a dose response relationship in smoking cessation prior to or after bypass, equalized patencies. A more recent study, published in JVS in September, queried the VSGNE, 1789 lower extremity bypasses, 971 were nonsmokers, 818 were smokers,

and what they found was that primary patency at two years was 48% in smokers, versus 61% in nonsmokers, and when they propensity matched these patients, there was even a greater difference. 10 year survival was also decreased. And in another article,

published in August of this year in JVS, again a VSGNE study, over 2,000 patients, almost 3,000 patients with lower extremity bypass for claudication. The results looked at MALE, amputation-free survival, limb loss, death, major limb events or death,

and they found that current smoking was a significant predictor of major adverse limb events, and major adverse limb events or death. But do active smokers have worse outcomes after endovascular interventions? So, let's look at the literature again.

And there is none. The only paper I could find was a Markov decision analysis, in which compared revascularization in active smokers to medical management, this was a retrospective study, and their results demonstrated better quality of life in smokers after revascularization versus medical therapy.

The quality of life was similar, after revascularization in nonsmokers and smokers, and there was no increase in amputation rates up to 36 months. Also, 26% of the folks that were revascularized, quit tobacco use after their quality of life was improved.

So we decided to do a small study at my hospital. The outcome of endovascular interventions in active smokers with lifestyle limiting claudication versus nonsmokers. This was retrospective. 138 total patients with endovascular intervention for claudication, 47 were current tobacco users,

91 were never or former smokers. The primary endpoints were reintervention, secondary endpoints, surgical bypass, limb loss, MI, stroke and death. And here you can see, as in most studies, the smokers were a younger population,

and anticoagulation, in our patient population, was more common. As far as comorbidities, they were more common, as in most studies, in the nonsmoking group. And in a mean followup of 3.6 years for both groups, there was no statistically significant difference

between the two groups for any of the outcome measures. So in conclusion, active smokers with lifestyle limiting claudication, we would advocate, of course, smoking cessation. Outcomes with respect to reintervention, surgical bypass and limb loss appear to be equivalent in these two groups.

We feel that these patients should not be denied endovascular intervention, and improved quality of life after intervention may result in an increase in smoking cessation in this patient population. Limitations are obvious, this was a very small study,

and retrospective, and we are actually extending this study to look at several hundred additional patients. So I thank you for your attention.

- Thank you, and thank you Dr. Veith for the opportunity to present. So, acute aortic syndromes are difficult to treat and a challenge for any surgeon. In regionalization of care of acute aortic syndromes is now a topic of significant conversation. The thoughts are that you can move these patients

to an appropriate hospital infrastructure with surgical expertise and a team that's familiar with treating them. Higher volumes, better outcomes. It's a proven concept in trauma care. Logistics of time, distance, transfer mortality,

and cost are issues of concern. This is a study from the Nationwide Inpatient Sample which basically demonstrates the more volume, the lower mortality for ruptured abdominal aortic aneurysms. And this is a study from Clem Darling

and his Albany Group demonstrating that with their large practice, that if they could get patients transferred to their central hospital, that they had a higher incidence of EVAR with lower mortality. Basically, transfer equaled more EVARs and a

lower mortality for ruptured abdominal aortic aneurysms. Matt Mell looked at interfacility transfer mortality in patients with ruptured abdominal aortic aneurysms to try to see if actually, transfer improved mortality. The take home message was, operative transferred patients

did do better once they reached the institution of destination, however they had a significant mortality during transfer that basically negated that benefit. And transport time, interestingly did not affect mortality. So, regional aortic management, I think,

is something that is quite valuable. As mentioned, access to specialized centers decrease overall mortality and morbidity potentially. In transfer mortality a factor, transport time does not appear to be. So, we set up a rapid transport system

at Keck Medical Center. Basically predicated on 24/7 coverage, and we would transfer any patient within two hours to our institution that called our hotline. This is the number of transfers that we've had over the past three years.

About 250 acute aortic transfers at any given... On a year, about 20 to 30 a month. This is a study that we looked at, that transport process. 183 patients, this is early on in our experience. We did have two that expired en route. There's a listing of the various

pathologies that we treated. These patients were transferred from all over Southern California, including up to Central California, and we had one patient that came from Nevada. The overall mortality is listed here. Ruptured aortic aneurysms had the highest mortality.

We had a very, very good mortality with acute aortic dissections as you can see. We did a univariate and multivariate analysis to look at factors that might have affected transfer mortality and what we found was the SVS score greater than eight

had a very, very significant impact on overall mortality for patients that were transferred. What is a society for vascular surgery comorbidity score? It's basically an equation using cardiac pulmonary renal hypertension and age. The asterisks, cardiac, renal, and age

are important as I will show subsequently. So, Ben Starnes did a very elegant study that was just reported in the Journal of Vascular Surgery where he tried to create a preoperative risk score for prediction of mortality after ruptured abdominal aortic aneurysms.

He found four factors and did an ROC curve. Basically, age greater than 76, creatinine greater than two, blood pressure less than 70, or PH less than 7.2. As you can see, as those factors accumulated there was step-wise increased mortality up to 100% with four factors.

So, rapid transport to regional aortic centers does facilitate the care of acute aortic syndromes. Transfer mortality is a factor, however. Transport mode, time, distance are not associated with mortality. Decision making to deny and accept transfer is evolving

but I think renal status, age, physiologic insult are important factors that have been identified to determine whether transfer should be performed or not. Thank you very much.

- Good morning, I would like to thank Dr. Veith, and the co-chairs for inviting me to talk. I have nothing to disclose. Some background on this information, patients with Inflammatory Bowel Disease are at least three times more likely to suffer a thrombo-embolic event, when compared to the general population.

The incidence is 0.1 - 0.5% per year. Overall mortality associated with these events can be as high as 25%, and postmortem exams reveal an incidence of 39-41% indicating that systemic thrombo-embolism is probably underdiagnosed. Thrombosis mainly occurs during disease exacerbation,

however proctocolectomy has not been shown to be preventative. Etiology behind this is not well known, but it's thought to be multifactorial. Including decrease in fibrinolytic activity, increase in platelet activation,

defects in the protein C pathway. Dyslipidemia and long term inflammation also puts patients at risk for an increase in atherosclerosis. In addition, these patients lack vitamins, are often dehydrated, anemic, and at times immobilized. Traditionally, the venous thrombosis is thought

to be more common, however recent retrospective review of the Health Care Utilization Project nationwide inpatient sample database, reported not only an increase in the incidence but that arterial complications may happen more frequently than venous.

I was going to present four patients over the course of one year, that were treated at my institution. The first patient is 25 year old female with Crohn's disease, who had a transverse colectomy one year prior to presentation. Presented with right flank pain, she was found to have

right sided PE, a right sided pulmonary vein thrombosis and a left atrial thrombosis. She was admitted for IV heparin, four days later she had developed abdominal pains, underwent an abdominal CTA significant for SMA occlusion prompting an SMA thrombectomy.

This is a picture of her CAT scan showing the right PE, the right pulmonary vein thrombosis extending into the left atrium. The SMA defect. She returned to the OR for second and third looks, underwent a subtotal colectomy,

small bowel resection with end ileostomy during the third operation. She had her heparin held post-operatively due to significant post-op bleeding, and over the next three to five days she got significantly worse, developed progressive fevers increase found to have

SMA re-thrombosis, which you can see here on her CAT scan. She ended up going back to the operating room and having the majority of her small bowel removed, and went on to be transferred to an outside facility for bowel transplant. Our second patient is a 59 year old female who presented

five days a recent flare of ulcerative colitis. She presented with right lower extremity pain and numbness times one day. She was found to have acute limb ischemia, category three. An attempt was made at open revascularization with thrombectomy, however the pedal vessels were occluded.

The leg was significantly ischemic and flow could not be re-established despite multiple attempts at cut-downs at different levels. You can see her angiogram here at the end of the case. She subsequently went on to have a below knee amputation, and her hospital course was complicated by

a colonic perforation due to the colitis not responding to conservative measures. She underwent a subtotal colectomy and end ileostomy. Just in the interest of time we'll skip past the second, third, and fourth patients here. These patients represent catastrophic complications of

atypical thrombo-embolic events occurring in IBD flares. Patients with inflammatory disease are at an increased risk for both arterial and venous thrombotic complications. So the questions to be answered: are the current recommendations adequate? Currently heparin prophylaxis is recommended for

inpatients hospitalized for severe disease. And, if this is not adequate, what treatments should we recommend, the medication choice, and the duration of treatment? These arterial and venous complications occurring in the visceral and peripheral arteries

are likely underappreciated clinically as a risk for patients with IBD flares and they demonstrate a need to look at further indications for thrombo-prophylaxis. Thank you.

- I'd like to thank Dr. Veith for this kind invitation and the committee as well. So these are my disclosures, there's none. So for a quick background regarding closure devices. Vascular closure devices have been around

for almost 20 years, various types. Manual compression in most studies have always been shown to be superior to vascular closure devices mainly because there's been no ideal device that's been innovated to be able

to handle all sorts of anatomies, which include calcified vessels, soft plaque, etc. So in this particular talk we wanted to look at to two particular devices. One is the Vascade vascular closure device

made by Cardiva and the other is the CELT arterial closure device made by Vasorum in Ireland. Both these devices are somewhat similar in that they both use a disc. The Vascade has a nitinol disc

as you can see here that's used out here to adhere to the interior common femoral artery wall. And then once tension is applied, a series of steps is involved to deploy the collagen plug

directly on to the artery which then allows it to expand over a period of time. The CELT is similar in that it also uses a stainless steel disc as you can see here. Requires tension up against the interior wall of the common femoral artery.

Nice and tight and then you screw on the top end of the device on to the interior wall of the artery creating a nice little cylinder that compresses both walls of artery. As far as comparability is concerned between the two devices you can see

here that they're both extravascular, one's nitinol, one's stainless steel. One uses a collagen material, the other uses an external clip in a spindle-type fashion. Both require about, anywhere between three to seven minutes of pressure

to essentially stop the tract ooze. But the key differences between the two devices, is the amount of time it takes for patients to ambulate. So the ambulation time is two hours roughly for Vascade, whereas for a CELT device

it's anywhere from being immediate off the table at the cath lab room to about 20 minutes. The data for Vascade was essentially showing the RESPECT trial which I'll summarize here, With 420 patients that was a randomized trial

to other manual compression or the device itself. The mean points of this is that the hemostasis time was about three minutes versus 21 minutes for manual compression. And time to ambulation was about 3.2 hours versus 5.7 hours.

No major complications were encountered. There were 1.1% of minor complications in the Vascade versus 7% in the manual compression arm. This was actually the first trial that showed that a actual closure devices

had better results than manual compression. The main limitations in the trial didn't involved complex femoral anatomy and renal insufficiency patients which were excluded. The CELT ACD trial involved 207 patients that were randomized to CELT or to manual

compression at five centers. Time to hemostasis was anywhere between zero minutes on average versus eight minutes in the manual compression arm. There was one complication assessed at 30 days and that was a distal embolization that occurred

early on after the deployment with a successfully retrieved percutaneously with a snare. So complication rate in this particular trial was 0.7% versus 0% for manual compression. So what are some pros and cons with the Vascade device?

Well you can see the list of pros there. The thing to keep in mind is that it is extravascular, it is absorbable, it's safe, low pain tolerance with this and the restick is definitely possible. As far as the cons are involved.

The conventional bedrest time is anywhere between two to three hours. It is a passive closure device and it can create some scarring when surgical exploration is necessary on surgical dissections.

The key thing also is you can not visualize the plug after deployment. The pros and cons of the CELT ACD device. You can see is the key is the instant definitive closure that's achieved with this particular device, especially in

calcified arteries as well. Very easy to visualize under fluoroscopy and ultrasound. It can be used in both antegrade and retrograde approaches. The key cons are that it's a permanent implant.

So it's like a star closed devised, little piece of stainless steel that sits behind. There's a small learning curve with the device. And of course there's a little bit of discomfort associated with the cinching under the (mumbles) tissue.

So we looked at our own experience with both devices at the Christie Clinic. We looked at Vascade with approximately 300 consecutive patients and we assessed their time to hemostasis, their time to ambulation,

and their time to discharge, as well as the device success and minor and major complications. And the key things to go over here is that the time to hemostasis was about 4.7 minutes for Vascade, at 2.1 hours for ambulation, and roughly an average

of 2.4 hours for discharge. The device success was 99.3% with a minor complication rate of .02% which we have four hematomas and two device failures requiring manual compression. The CELT ACD device we also similarly did

a non-randomized perspective single center trial assessing the same factors and assessing the patients at seven days. We had 400 consecutive patients enrolled. And you can see we did 232 retrograde. We did a little bit something different

with this one, we did we 168 antegrade but we also did direct punctures to the SFA both at the proximal and the mid-segments of the SFA. And the time to hemostasis in this particular situation was 3.8 minutes,

ambulation was 18.3 minutes, and discharge was at 38.4 minutes. We did have two minor complications. One of which was a mal-deployment of the device requiring manual compression. And the second one was a major complication

which was an embolization of the device immediately after deployment which was done successfully snared through an eighth front sheath. So in conclusion both devices are safe and effective and used for both

antegrade and retrograde access. They're definitely comparable when it comes, from the standpoint of both devices (mumbles) manual compression and they're definitely really cost effective in that they definitely do increase the

throughput in the cath lab allowing us to be able to move patients through our cath lab in a relatively quick fashion. Thank you for your attention.

- Alright, well thank you, everybody, for having me. Thanks, Larry for inviting me to give this talk. My only disclosure is that I am the vice president of operations for (clears throat), excuse me, Azura Vascular Care and we operate 65 office based laboratories and ambulatory surgery centers. So, the undertaking to go ahead

and become a ambulatory surgery center is massive and requires a tremendous amount of pre-planning. You have to have a very sound financial model, you have to have a stable physician pool, you have to have a good patient referral base. And without lining up all those elements first,

you are sort of dead in the water. So the first thing to understand is that a physician's office and an ambulatory surgery center are separate and distinct entities. Today if you have a physician's office through an extension of your practice

you can then set up an Angio Suite, you can then perform procedures on the patients as needed. But once you're an ambulatory surgery center, you no longer have sort of the office space part. So you can't do ultrasounds, well you can do them, you just can't bill for them, right.

And so you can't concurrently run a physician's office practice out of the ambulatory surgery center, it's actually not permitted in the Medicare conditions for coverage. So that changes things for sure.

And then so if you're really based out of a physician's office and you have your Endo Suite there, you sort of have to have two offices moving forward. Anyway, you must comply with Conditions for Coverage. The ASC is now subject to State, CMS, and Accrediting bodies and they can show up at any time.

It's a major difference in the way you practice. If it's your doctor's office right now, you know, maybe there's a inspection once a year for a radiation certificate or something like that, but there's really not a whole lot of oversight. ASCs have very strict physical plant guidelines.

There are enhanced staffing requirements, circulating nurses, facility administrators, directors of nursing, all of these extra things that add a very significant amount of cost. You also have to have governance, right. So there's a governing body, a Medical Executive Committees

and requirements, right. Now they're not difficult but there's all this extra documentation that has to go along with it which is just time consuming, burdensome, task oriented. There's disclosures of ownership.

There's a quality improvement program which you have to show that you're doing and documented, and the accrediting bodies, if you don't have it right, they could cite you and it's really a lot of extra work. You need transfer agreements and patient satisfaction surveys,

all these kinds of things. Alright, other ASC fact, okay. In a typical two room facility, you can get away with essentially 35 hundred square feet versus five thousand square feet in an ASC. You would instead of typically having six employees,

you need nine employees, adding all this extra expense. The expertise of the staff is very different, alright. You actually need facility administrators, not just, you can't just pluck a nurse out of their daytime job of seeing patients on the floor and say, okay, now you're facility administrator.

They have to understand regulations, they have to understand the Medicare Conditions for Coverage, et cetera. They have also very extended timeline, which I'll show you on another slide, but the regulatory requirements from life safety,

fire safety, staffing requirements, state licensure, Medicare Deem status, accreditation, all of these things factor into the overall cost to set up an OBL, depending on how you do it, is probably about 1.5 million dollars, versus an ASC at 3.5 million dollars.

So the 800 pound gorilla in states in New York, and about 25 or 30 other states is the process of getting a certificate of need. So if you're in a certificate of need state, it's a whole thing, right. So first you have to get the CON.

The CON then allows you to get state licensure. The state licensure then allows you to apply for Medicare Deem status to an accrediting body. Once you have your Deem status, then you can submit for your PTAN, your physician transaction number, so that you can actually bill Medicare for facility fees,

and then and only then can you then initiate the entire process of getting your private payor contracts. So, all that being said, your application for a CON could be outright rejected. You could be blocked by local hospitals. You could be blocked by local politics.

There's a tremendous amount of issues. Now the one thing that's interesting, if you're in a state that doesn't have a Certificate of Need process, then one of the things that's interesting is they sort of, you sort of get tied up in the local fire marshal, the Department of Health

and this very disjointed Department of Health survey. The Certificate of Need at least, at the very least, allows you to kind of cruise through the process, so that you can, at least you understand your pathway. In states that don't even have a CON process, it can be very disjointed.

Now if you're thinking about building a new facility, well, that's about two to two and a half million dollars. If you're thinking of retrofitting, I'd go by the rule of 200 thousand. So if you need a semi-restricted corridor, and you have to move walls,

that'll cost you about 200 thousand. If you, you're going to need 20 air exchanges per hour in your procedure room, that's a hard requirement. You have to be, you have to get stuff that certifies that you are achieving that, right. That new HVAC system will cost you 200 thousand dollars.

You need three electrical panels. One to power the HVAC, one to power the electrical outlets and one to power the overhead lighting. I mean, the requirements are very, very different. Then, maybe now you're going to need a generator. Well, am I in a building where you're going to

put the generator on the roof, then the fire marshal tells me I can't store the gasoline on the roof, it has to be on the ground, and then you wind up in this big back and forth fight as to where you can put your generator.

Just for time's sake, this is a basic floor plan with semi-restricted corridors, eight foot wide hallways, enough seating for 30 people. The staffing requirements change significantly, in terms of you need a facility administrator, somebody who really knows it.

Now god forbid the facility administrator's on vacation when the state shows up or when an accrediting body shows up so you better have your DON, your director of nursing, all tuned up so that she knows how to answer the questions and knows where all of your paperwork are because otherwise you could be cited

and you could be sunk and it's very burdensome. But the difference in staff costs for typical two room facility is probably about 300 thousand dollars cumulatively. For your hours of operation, right, so now you have a business that's operating as an OBL,

now you want to convert it to an ASC, well that's great. But now you don't have your private payor contract, so what are you going to do? You going to start rejecting patients? So, no, you're not going to do that. So either you're going to lose money on those patients

or you're going to wind up having to form this hybrid operation where you flip back and forth, one day to the next day, et cetera. And the problem with doing that is each one requires its own tax ID number, its own NPI, its own billing codes. And then the staff has to be trained

that they're dedicated to one versus the other. This is your timeline to show you how everything lines up, in terms of your construction, then getting your state licensure, then getting your Medicare accreditation, and then only after you get your Medicare accreditation,

can you then submit for your PTAN, which then takes 90 days. And then only after you get your PTAN, can you being your private payor contracting. So, in conclusion, it requires more time, more staff, more oversight and regulation. The complex hours of operation ought

to maintain your existing patient base. You need a payor contracting strategy. It's probably an additional two million dollars to build out an ASC, including the working capital requirement. So for the solo practitioners that were out there thinking about it,

unless there's a very compelling financial reason to convert, it's probably best to stay an OBL at this time. Thank you.

- Well, thank you Frank and Enrico for the privilege of the podium and it's the diehards here right now. (laughs) So my only disclosure, this is based on start up biotech company that we have formed and novel technology really it's just a year old

but I'm going to take you very briefly through history very quickly. Hippocrates in 420 B.C. described stroke for the first time as apoplexy, someone be struck down by violence. And if you look at the history of stroke,

and trying to advance here. Let me see if there's a keyboard. - [Woman] Wait, wait, wait, wait. - [Man] No, there's no keyboard. - [Woman] It has to be opposite you. - [Man] Left, left now.

- Yeah, thank you. Are we good? (laughs) So it's not until the 80s that really risk factors for stroke therapy were identified, particularly hypertension, blood pressure control,

and so on and so forth. And as we go, could you advance for me please? Thank you, it's not until the 90s that we know about the randomized carotid trials, and advance next slide please, really '96 the era of tPA that was

revolutionary for acute stroke therapy. In the early 2000s, stroke centers, like the one that we have in the South East Louisiana and New Orleans really help to coordinate specialists treating stroke. Next slide please.

In 2015, the very famous HERMES trial, the compilation of five trials for mechanical thrombectomy of intracranial middle and anterior cerebral described the patients that could benefit and we will go on into details, but the great benefit, the number needed to treat

was really five to get an effect. Next slide. This year, "wake up" strokes, the extension of the timeline was extended to 24 hours, increase in potentially the number of patients that could be treated with this technology.

Next please. And the question is really how can one preserve the penumbra further to treat the many many patients that are still not offered mechanical thrombectomy and even the ones that are, to get a much better outcome because not everyone

returns to a normal function. Next, so the future I think is going to be delivery of a potent neuroprotection strategy to the penumbra through the stroke to be able to preserve function and recover the penumbra from ongoing death.

Next slide. So that's really the history of stroke. Advance to the next please. Here what you can see, this is a patient of mine that came in with an acute carotid occlusion that we did an emergency carotid endarterectomy

with an neuro interventionalist after passage of aspiration catheter, you can see opening of the middle cerebral M1 and M2 branches. The difference now compared to five, eight, 10 years ago is that now we have catheters in the middle cerebral artery,

the anterior cerebral artery. After tPA and thrombectomy for the super-selective, delivery of a potent neuroprotective agent and by being able to deliver it super-selectively, bioavailability issues can be resolved, systemic side effects could be minimized.

Of course, it's important to remember that penumbra is really tissue at risk, that's progression towards infarction. And everybody is really different as to when this occurs. And it's truly all based on collaterals.

So "Time is brain" that we hear over and over again, at this meeting there were a lot of talks about "Time is brain" is really incorrect. It's really "Collaterals are brain" and the penumbra is really completely based on what God gives us when we're born, which is really

how good are the collaterals. So the question is how can the penumbra be preserved after further mechanical thrombectomy? And I think that the solution is going to be with potent neuroprotection delivery to the penumbra. These are two papers that we published in late 2017

in Nature, in science journals Scientific Reports and Science Advances by our group demonstrating a novel class of molecules that are potent neuroprotective molecules, and we will go into details, but we can discuss it if there's interest, but that's just one candidate.

Because after all, when we imaged the penumbra in acute stroke centers, again, it's all about collaterals and I'll give you an example. The top panel is a patient that comes in with a good collaterals, this is a M1 branch occlusion. In these three phases which are taken at

five second intervals, this patient is probably going to be offered therapy. The patients that come in with intermediate or poor collaterals may or may not receive therapy, or this patient may be a no-go. And you could think that if neuroprotection delivery

to the penumbra is able to be done, that these patients may be offered therapy which they currently are not. And even this patient that's offered therapy, might then leave with a moderate disability, may have a much better functional

independence upon discharge. When one queries active clinical trials, there's nothing on intra arterial delivery of a potent neuroprotection following thrombectomy. These are two trials, an IV infusion, peripheral infusion, and one on just verapamil to prevent vasospasm.

So there's a large large need for delivery of a potent neuroprotection following thrombectomy. In conclusion, we're in the door now where we can do mechanical thrombectomy for intracranial thrombus, obviously concomitant to what we do in the carotid bifurcation is rare,

but those patients do present. There's still a large number of patients that are still not actively treated, some estimate 50 to 60% with typical mechanical thrombectomy. And one can speculate how ideally delivery of a potent neuroprotection to this area could

help treat 50, 60% of patients that are being denied currently, and even those that are being treated could have a much better recovery. I'd like to thank you, Frank for the meeting, and to Jackie for the great organization.

- Thank you Dr. Veith for an invitation to be here. These are our disclosures. We're fortunate to have funding from VA HSR&D for this work. Decision aids help patients make decisions about medical treatment, such as steroids versus biologics for things like arthritis.

Or medical versus surgical treatments for things like degenerative joint disease. Decision aids are uncommonly used for decisions about surgical treatment. Such as the options that face patients facing abdominal aortic aneurysm repair,

which as well all know are options like open surgery, which is invasive, but has a long recovery, but is likely durable over time. Or endovascular repair, which is, of course, less invasive with a shorter recovery, but may have problems with durability.

We design the preferences for open versus endovascular repair or prove AAA trial and this study has two objectives. First was to implement a decision aid, which is designed to help Veterans choose between an open and endovascular repair for their abdominal aortic aneurysm.

Of course, taking place in Veterans Hospitals across the US. And then second, to test if the decision aid makes it more likely for Veterans to receive the type of aneurysm repair that is aligned with their treatment preferences.

We are going to achieve these objectives, we hope, via a randomized clinical trial. I'll tell you briefly about that. We're going to study Veterans who have an existing abdominal aortic aneurysm that measures at least 5.0 cm in diameter that are anatomic and physiologic candidates

for open and endovascular repair. At ten control sites, the Veterans will take a simple survey and have their vascular surgery consultation. And simple surveys for their surgeons will follow thereafter. At 10 intervention sites, the process is identical

with the exception of an introduction of a decision aid. This decision aid was designed in England by Roger Greenhall, Jana Paul and others as part of the Picker Institute and provides a balanced view of the advantages and disadvantages of

both open and endovascular repair. We then followed the Veterans for two years to see what happens when the repair ultimately occurs and our main outcome measure was whether or not they preferred aneurysm repair type turned out to be their actual repair type.

We had performed this study, and I'm very grateful to my colleagues across the country at the 20 sites who are going to perform this trial. We began enrollment a little over a year ago. We're going to enroll 240 patients, I hope. We've enrolled 181 patients thus far,

so we're about 3/4 of the way there. And many of our sites, especially those in Gainesville, Ann Arbor, Buffalo, Salt Lake City, Tampa, Tucson, Pittsburgh and others have either completed their enrollments or are close to doing them. And while our objectives are to answer

these two study questions, I can't do that quite just yet. But we can examine the information sources that Veterans have used thus far when facing this decision. We asked Veterans questions like who have you talked to about if the surgical treatment options available to you if you needed an operation?

52% of our study participants thus far said they didn't talk to anybody. They didn't talk to their PCP at all about their AAA repair options. We asked them who their main source of information was about open surgical repair and again 41% of patients

reported having no information at all about open surgical repair of AAA and while only one in five cited a primary care physician as their main source of information. We asked the Veterans the same question about endovascular repair.

Again, 40% of patients received no information about EVAR, 17% got information from their primary care physician, about 10% of patients, a number lower than we expected, used the internet. Finally, we asked patients, has your view of the different surgical treatment options available been influenced

by anybody in your, among your medical advisors. 50% of patients reported that their view had not been influenced by anyone. We felt this led us be safe to conclude that while our future work will report the actual preferences for repair types

and the effects of this decision support, we found that half the patients with abdominal aortic aneurysm meeting criteria for repair had not yet discussed their treatment methods with anyone prior to meeting with a vascular surgeon. I believe this shows that the burden of explanation

for patients facing abdominal aortic aneurysm repair rests squarely on the shoulders of those of us in the vascular community. Thank you.

- These are my disclosures, as it pertains to this talk. FEVAR has become increasingly common treatment for juxtarenal aneurysm in the United States since it's commercial release in 2012. Controversy remains, however, with regard to stenting the SMA when it is treated with a single-wide, 10 mm scallop in the device.

You see here, things can look very similar. You see SMA treated with an unstented scallop on the left and one treated with the stented SMA on the right. It has been previously reported by Jason Lee that shuttering can happen with single-wide scallops of the SMA and in their experience

the SMA shuttering happens to different degree in patients, but is there in approximately 50% of the patients. But in his experience, the learning curve suggests that it decreases over time. At UNC, we use a selective criteria for stenting in the SMA. We will do a balloon test in the SMA,

as you see in the indication, and if the graft is not moved, then our SMA scallop is appropriate in line. If we have one scallop and one renal stent, its a high likelihood that SMA scallop will shift and change over time. So all those patients get stented.

If there is presence of pre-existing visceral stenosis we will stent the SMA through that scallop and in all of our plans, we generally place a 2 mm buffer, between the bottom edge of the scallop and the SMA. We looked over our results and 61 Zenith fenestrated devices performed over a short period of time.

We looked at the follow-up out up to 240 days and 40 patients in this group had at least one single wide scallop, which represented 2/3 of the group. Our most common configuration as in most practices is too small renal fenestrations and one SMA scallop.

Technically, devices were implanted in all patients. There were 27 patients that had scallops that were unstented. And 13 of the patients received stented scallops. Hospital mortality was one out of 40, from a ruptured hepatic artery aneurysm post-op.

No patients had aneurysm-related mortality to the intended treated aneurysm. If you look at this group, complications happen in one of the patients with stented SMA from a dissection which was treated with a bare metal stent extension at the time

of the initial procedure. And in the unstented patients, we had one patient with post-op nausea, elevated velocities, found to have shuttering of the graft and underwent subsequent stenting. The second patient had elevated velocities

and 20-pound weight loss at a year after his treatment, but was otherwise asymptomatic. There is no significant difference between these two groups with respect to complication risk. Dr. Veith in the group asked me to talk about stenting choice

In general, we use the atrium stent and a self-expanding stent for extension when needed and a fenestrated component. But, we have no data on how we treat the scallops. Most of those in our group are treated with atrium. We do not use VBX in our fenestrated cases

due to some concern about the seal around the supported fenestration. So Tips, we generally calculate the distance to the first branch of the SMA if we're going to stent it. We need to know the SMA diameter, generally its origin where its the largest.

We need to position the imaging intensifier orthogonal position. And we placed the stent 5-6 mm into the aortic lumen. And subsequently flare it to a 10-12 mm balloon. Many times if its a longer stent than 22, we will extend that SMA stent with a self-expanding stent.

So in conclusion, selective stenting of visceral vessels in single wide scallops is safe in fenestrated cases during this short and midterm follow-up if patients are carefully monitored. Stenting all single wide scallops is not without risk and further validation is needed

with multi-institution trial and longer follow-up

Disclaimer: Content and materials on Medlantis are provided for educational purposes only, and are intended for use by medical professionals, not to be used self-diagnosis or self-treatment. It is not intended as, nor should it be, a substitute for independent professional medical care. Medical practitioners must make their own independent assessment before suggesting a diagnosis or recommending or instituting a course of treatment. The content and materials on Medlantis should not in any way be seen as a replacement for consultation with colleagues or other sources, or as a substitute for conventional training and study.